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 I 
ABSTRACT 
Imaging molecular techniques including PET, CT, MRI allow to detect and to 
monitor normal and pathological conditions non-invasively in clinic. The recent 
development of dedicated small animal instruments together to the availability of 
appropriate animal models of disease has allowed the use of these methods in 
preclinical research with the possibility to transfer directly the obtained results in 
clinic. 
In this thesis’s work we characterized two preclinical oncology models through the 
use of an animal PET instrument focusing on two processes correlated to tumour 
growth such as hypoxia and inflammation. 
Tissue hypoxia is considered as a negative prognostic factor both for answer to 
pharmacological and radiant therapy and for tumour progression and invasiveness. 
Consequently, identification and localization of hypoxic areas within the tumour 
have an important interest in clinical diagnostic. To this aim, BALB/c nu/nu mice 
were inoculated with murine cells of mammary adenocarcinoma (EMT-6) and with 
human cells of prostate adenocarcinoma (PC-3) and pharingeal cancer (FaDu). 
Animals were monitored using two hypoxic radiopharmaceutical recently 
developed, [18F]FAZA and [64Cu]ATSM at two different times, using PET and 
autoradiography. In parallel, an in vitro evaluation of specific hypoxic markers such 
as carbonic anhydrase IX and cupper transporters (Ctr-1 and ATP7B) was 
performed. In FaDu model we confirmed the same [64Cu]ATSM distribution at the 
two analyzed times, that is similar to that of [18F]FAZA. On the contrary, EMT-6 and 
PC-3 models showed a time-dependent [64Cu]ATSM uptake, with a distribution at 
late time (24hrs post injection) similar to that of [18F]FAZA. The different distribution 
of [64Cu]ATSM can be only partially explained by the different cupper pumps 
localization observed in vitro. Other factors such red-ox and cellular pH may 
influence [64Cu]ATSM uptake. PET imaging is an interesting method to identify and 
monitor tumour hypoxia in a non invasive way but it needs further studies that 
associate metabolic changes to proteomic pattern changes. 
Positron Emission Tomography (PET) imaging with [18F]2-fluorine-2-deoxy-D-
glucose-PET ([18F]FDG-PET) is widely used in neoplastic patients for disease 
assessment and evaluation of treatment efficacy. Results interpretation must take 
into account the contribution of inflammatory cells that infiltrate growing tumours for 
[18F]FDG uptake. In this work, we established a preclinical model of peritoneal 
carcinomatosis to verify the actual contribution of macrophages to signals obtained 
with [18F]FDG-PET. Groups of mice with peritoneal carcinosis were longitudinally 
evaluated with [18F]FDG-PET. Intraperitoneal depletion of macrophages was 
achieved by an approach that proved to be safe and effective, i.e. administration of 
clodronate encapsulated into liposomes. Sham-liposomes were used in control 
animal cohorts. Using [18F]FDG-PET we detected and monitored peritoneal lesions’ 
growth, with a good correlation between the real neoplastic lesions extension and 
that measured using [18F]FDG-PET. Macrophage depleted animals showed a 
substantial drop in tumour growth. In conclusion, [18F]FDG-PET imaging allows the 
non-invasive detection of peritoneal adenocarcinoma lesions and macrophages are 
directly and indirectly involved in [18F]FDG uptake by promoting tumour growth and 
spreading in the peritoneal cavity.  
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SOMMARIO 
Le tecniche di imaging molecolare quali PET, CT, MRI permettono di visualizzare e 
monitorare condizioni normali e patologiche in modo non invasivo nell’uomo. Il 
recente sviluppo di strumentazione dedicata al piccolo animale e di specifici 
modelli di malattia ha permesso l’utilizzo di queste tecniche anche a livello 
preclinico, con la possibilità di trasferire i risultati ottenuti direttamente in clinica. 
In questo lavoro di tesi ci siamo occupati di caratterizzare due modelli preclinici di 
lesione tumorale tramite l’impiego della PET animale, focalizzando l’attenzione su 
due processi correlati alla crescita tumorale quali l’ipossia e l’infiammazione. 
L’ipossia tessutale rappresenta un fenomeno sfavorevole dal punto di vista 
prognostico sia in termini di risposta alla terapia farmacologica e radiante che in 
termini di progressione e invasività del tumore. Di conseguenza è di particolare 
interesse riuscire a localizzare e identificare le aree ipossiche all’interno del 
tumore. A tale scopo, topi BALB/c nu/nu sono stati inoculati con cellule murine di 
carcinoma mammario (EMT-6) e con cellule umane di adenocarcinoma prostatico 
(PC-3) e di carcinoma della faringe (FaDu). Gli animali sono stati poi monitorati 
utilizzando due traccianti ipossici di recente sviluppo, [18F]FAZA e [64Cu]ATSM a 
due tempi diversi, tramite PET e autoradiografia. In parallelo, è stata fatta una 
valutazione in vitro dei marker specifici dell’ipossia quali l’anidrasi carbonica IX e 
dei trasportatori del rame (Ctr-1 e ATP7B). Nel modello FaDu abbiamo confermato 
la stessa distribuzione di [64Cu]ATSM ai due tempi analizzati, che è risultata simile 
a quella di [18F]FAZA. Al contrario, i modelli EMT-6 e PC-3 mostrano un uptake di 
[64Cu]ATSM dipendente dal tempo, con una distribuzione tardiva (24h 
dall’iniezione) più simile a quella di [18F]FAZA. La differente distribuzione di 
[64Cu]ATSM può essere spiegata solo parzialmente dalla diversa localizzazione 
delle pompe del Cu osservata in vitro. Altri fattori come il potenziale red-ox e il pH 
cellulare potrebbero influenzare l’uptake di [64Cu]ATSM. L’imaging PET risulta 
essere un metodo interessante per poter identificare e monitorare l’ipossia 
tumorale in modo non invasivo ma necessita di ulteriori studi che associno i 
cambiamenti metabolici ai cambiamenti dei pattern proteomici.  
L’imaging PET con [18F]2-fluoro-2-deossi-D-glucosio ([18F]FDG) è largamente 
utilizzato in pazienti con neoplasia per la valutazione della malattia e per l’efficacia 
del trattamento. L’interpretazione dei risultati deve tenere conto del contributo delle 
cellule infiammatorie che infiltrano il tumore per l’uptake di [18F]FDG. In questo 
lavoro, abbiamo sviluppato un modello preclinico di carcinosi peritoneale per 
verificare il contributo dei macrofagi nel segnale ottenuto con PET-[18F]FDG. 
Gruppi di topi con carcinosi peritoneale sono stati monitorati longitudinalmente 
tramite PET-[18F]FDG. I macrofagi sono stati depletati nel peritoneo utilizzando un 
approccio sicuro ed efficace, ovvero la somministrazione di clodronato incapsulato 
in liposomi. Liposomi vuoti sono stati somministrati nel gruppo controllo. Tramite 
PET-[18F]FDG siamo riusciti a visualizzare e monitorare la crescita delle lesioni con 
una buona correlazione tra l’estensione reale delle lesioni e quella misurata tramite 
PET-[18F]FDG. Gli animali depletati hanno mostrato una significativa riduzione 
della crescita tumorale. In conclusione l’imaging PET-[18F]FDG permette il 
monitoraggio non invasivo di lesioni tumorali intraperitoneali e i macrofagi 
contribuiscono all’uptake di [18F]FDG in modo sia diretto che indiretto promuovendo 
la crescita tumorale e la diffusione nella cavità peritoneale. 
 III 
INDEX 
ABSTRACT……………………………………………………………….....  I 
SOMMARIO…………………………………………………………………. II 
LIST OF SYMBOLS…………………………………………………….....  VI 
1. INTRODUCTION…………………………………………………………. 1 
1.1. Molecular imaging………………………………….…………….... 2 
1.2. Positron Emission Tomography, PET………………………….. 3 
1.2.1. Physical principles……………………………………...…….. 3 
1.2.1.1. Acquisition of events in coincidence…………………………. 3  
1.2.1.2. Spatial resolution…………………………………………………  4 
1.2.1.3. Detector system…………………………………………………... 5 
1.2.1.4. Images acquisition and reconstruction………………………. 5 
1.2.2. PET and preclinical imaging………………………………… 7 
1.2.3. Tomographs for small animals……………………………... 8 
 1.2.3.1 YAP-(S)PET II…………………………………………………….... 9 
1.2.4. PET application………………………………………………. 10 
1.3. Tumour and hypoxia……………………………………..………  12 
1.3.1. Pathogenesis of tumour hypoxia..…………………………12 
1.3.2. HIF………………………………………………………………. 13 
1.3.2.1. HIF structures……………………………………………………. 13 
1.3.2.2. Role of HIF in hypoxia………………………………………….. 14 
1.3.3. Glycolysis and respiration………………………………..... 17 
1.3.4. Hypoxia and therapy resistance…………………………..  20 
1.3.5. In vivo measurement of tissue hypoxia………………….. 21 
1.3.5.1. Biopsy specimens…………………………………….………… 21 
1.3.5.2. Polarographic electrodes……………………………………… 21 
1.3.5.3. Imaging techniques…………………………………………….. 22  
1.3.5.3.1. BOLD-MRI……………………………………………………. 22 
1.3.5.3.2. PET………………………………………………………….… 22 
1.4. Cancer and inflammation……………………………………….. 27 
1.4.1. The role of macrophages…………………………………… 27 
1.4.1.1 Depletion of macrophages: clodronate……………………… 31 
1.4.2. [18F]FDG-PET and inflammation…………………………… 35 
1.4.3. Structure and function of peritoneum……………………. 36 
1.4.4. Peritoneal liquid……………………………………………… 38 
1.4.5. Peritoneal carcinosis………………………………………... 38 
 IV 
1.4.5.1. Pathological changes in peritoneal liquid………………….. 39 
1.4.6. Diagnosis and monitoring of peritoneal cancer………... 39 
1.4.7. Preclinical model of peritoneal carcinosis……………… 42 
2. AIM………………………………………………………….……………. 43 
3. HYPOXIA MODEL……………………………………………………… 45 
3.1. Materials and methods…………………………………………... 46  
3.1.1. Cellular lines………………………………………………….. 46 
3.1.2. Animal models………………………………………………... 46 
3.1.3. Study design………………………………………………….. 46 
3.1.4. PET studies…………………………………………………… 46 
3.1.5. PET images analysis………………………………………… 47 
3.1.6. Dual-tracer ex-vivo autoradiography…………………….. 47 
3.1.7. Immunohistochemistry analysis………………………….. 48 
3.2. Results………………………………………………………………48 
3.2.1. Comparison of intratumoural uptake of [18F]FDG and 
[18F]FAZA in a longitudinal in vivo PET study…………………. 48 
3.2.2. Comparison of intratumoural uptake of [18F]FAZA and 
[64Cu]ATSM at early and late time in vivo by PET and ex-vivo by 
dual tracers autoradiography……………………………………... 53 
3.2.3. Immunohistochemistry analysis………………………….. 56 
3.3. Discussion………………………………………………………… 57 
4. INFLAMMATION MODEL…………………………………………….. 59 
4.1. Materials and methods………………………………………….. 60 
4.1.1. Mice…………………………………………………………….. 60 
4.1.2. Cells and tumour analysis………………………………….. 60 
4.1.3. Study design………………………………………………….. 60 
4.1.4. PET studies…………………………………………………… 61  
4.1.5. Image analysis……………………………………………….. 61 
4.1.6. Histological analysis………………………………………... 62 
4.1.7. Viability and apoptosis in vitro assays………………….. 62 
4.1.8. Statistical analysis…………………………………………... 63 
4.2. Results……………………………………………………………... 63  
4.2.1. Experimental model of peritoneal carcinomatosis and 
[18F]FDG distribution……………………………………………….. 63 
4.2.2. Relative contribution of neoplastic cells and tumour 
associated phagocytes to [18F]FDG uptake…………………….. 64 
4.2.3. Quantification and correlations analysis………………... 67 
 V 
4.3. Discussion…………………………………………………………. 70 
5. CONCLUSION………………………………………………………….. 72 
REFERENCES…………………………………………………………….. 74 
WORKS AND CONGRESS ATTENDENCE…………………………… 81 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 VI 
LIST OF SYMBOLS  
ANG-1 and -2: angiopoietins 
ARNT: arylhydrocarbon receptor nuclear translocator  
ATP7A: Menkes protein, copper exporter 
ATP7B: Wilson protein, copper exporter 
bFGF: basic fibroblast growth factor  
BOLD-MRI: blood oxygenation level dependent-magnetic resonance imaging 
CAIX: carbonic anhydrase IX 
CBP: CREB binding protein 
Clodrolip: clodronate incapsulated in liposomes 
cMyc: oncogenic factor 
CXCR4: C-X-C chemokine receptor type 4 
COX-2: cyclooxygenase 2 
CT: computed tomography 
Ctr1: Copper transporter 
[64Cu]ATSM: [64Cu]diacetyl-bis(N4-methylthiosemicarbazone) 
DC: dendritic cells 
ECM: extracellular matrix 
EGF: epidermal growth factor 
EM: expectation maximization 
[18F]FDG: 2-[F-18]Fluorine-2-deoxy-D-glucose  
[18F]FLT: [18F]Fluorine-levo-thymidine  
fMRI: functional magnetic resonance imaging 
FBP: filter back projection 
FIH-1: factor inhibiting HIF-1 
[18F]FAZA: [18F]fluoroazomycin-arabinofuranoside  
[18F]FMISO: [18F]Fluoromisonidazole 
FLT-1 and FLK-1: VEGF receptors 
FOV: field of view 
GLUT-1 and GLUT-3: glucose transporters 
HGF: hepatocytes growth factor  
HIF-1: hypoxia inducible factor 1 
HK: hexokinase 
HREs: hypoxia response elements  
HSPs: heat shock proteins 
[124I]IAZA: [124I]iodoazomycin arabinoside 
iNOS: inducible NO synthase 
LDH-A: lactate dehydrogenase A 
LOR: line of response 
LOX: lysyl oxidase 
M1 and M2: macrophage type 1 and type 2 
MAPK: mitogen-activated protein kinase 
MCSF: macrophage colony stimulating factor 
MCT1 and MCT4: monocarboxylate transporter 1 and 4 
MIP-1α: macrophages inflammatory protein 1α 
MMP-2 and MMP-9: matrix metalloproteinases 
MRI: magnetic resonance imaging 
MRS: magnetic resonance spectroscopy 
 VII 
NKc: natural killer cells 
OAA: oxaloacetate 
ODD: oxygen-dependent degradation domain   
PAI-1: plasminogen activator inhibitor-1 
PDGF-B: platelet-derived growth factor B 
PDK: pyruvate dehydrogenase kinase 
PET: positron emission tomography 
PI3K: phosphatidylinositol 3-kinase 
PHD1, 2 and 3: proline hydroxylases 
PPP: pentose phosphate pathway 
PTEN: negative regulator of PI3K 
pVHL: product of the von Hippel-Lindau tumor suppressor gene 
ROI: region of interest 
SDF-1: stromal derived factor 1 
Shamlip: liposomes without clodronate 
SPECT: single photon emission computerized tomography 
SUV: standardized uptake value 
TAM: tumour associated macrophage 
TCA: tricarboxylic acid 
TGF-β: transforming growth factor 
TNF-α: tumour necrosis factor alpha: 
TPO: thrombopoietin 
uPA: urokinase-type plasminogen activator 
uPAR: uPA receptor 
US: ultrasounds 
VEGF: vascular endothelial growth facto 
VOR: volume of response 
 
 1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1. INTRODUCTION
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1.1. Molecular imaging 
 
Molecular and cellular imaging is a branch of biomedical sciences including 
tomographic techniques such as PET (positron emission tomography), SPECT 
(single photon emission computerized tomography), CT (computed tomography), 
MRI (magnetic resonance imaging) and non-tomographic techniques like US 
(ultrasounds) for the study and the characterization of molecular and cellular 
processes in living organisms in normal and pathological conditions. In general, 
these techniques allow with some limitations to study specific molecular target or 
tissues characteristics and their changes during time, by evaluating the different 
pathological stages.   
Molecular imaging techniques need: 
a) the use of probes with high specificity for a target of interest;  
b) an adequate signal amplification;  
c) a sensitive system able to reproduce images with high resolution. 
For these reasons, primarily, research is focused on the selection of suitable 
molecules which are able to obtain an image of the biological process under study. 
These probes need specific characteristics to reach the target of interest including 
capability to cross biological barriers like vessels’ walls, interstitial and cellular 
membranes and capability to stay in circulation the time necessary to interact with 
the target before to be excreted and degraded. Moreover, low immunogenicity and 
absence of pharmacological effect itself are essential properties for the ligand.  
Second, research is focused on planning the strategies to amplify the signal 
because of low target concentrations which are in pico-nano moles order and 
finally on design of dedicated imaging system with high spatial resolution and 
sensitivity. 
The most used techniques to obtain molecular information from biological systems 
are PET and MRI thanks to their higher sensitivity and spatial resolution in 
comparison to other techniques. Positron emission tomography permits the study 
of cellular metabolism and biochemical reactions within the organism in normal and 
pathological conditions; on the other hand, magnetic resonance imaging permits to 
difference tissues on the basis of their water content and also to determine 
structural and volumetric changes due to pathological processes. Recently, new 
technologies are able to obtain further information for example functional Magnetic 
Resonance Imaging (fMRI) permits to obtain information on tissue perfusion, 
vascular volume and permeability and on the molecular and metabolic changes of 
tumours in cerebral studies; magnetic resonance spectroscopy (MRS) is able to 
visualize changes the concentration of organic molecules, different from water, 
formed by Carbon and Phosphor and thus applied to cellular metabolism studies. 
In addition, the conjugation of molecules with elements able to modify magnetic 
fields has open the potential extension of molecular imaging also to MRI. However, 
MRI has a lower sensitivity in comparison to Positron Emission Tomography, in fact 
in PET analysis radiotracers are administered in microdose which is <1/100 of 
active dose. In this way, using PET it is possible detect a process without 
perturbing the system. 
The most recent instruments combine complementary technologies as PET/CT and 
PET/MR which permit to combine morphological, functional and biochemical 
information. In this way it is possible to visualize and detect molecular signal 
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exploiting the potential and advantages of each single technology and limiting 
defects. 
 
1.2. Positron Emission Tomography, PET  
 
Positron Emission Tomography (PET) is an analytic imaging technique based on 
the use of compounds labelled with emitting positron radioisotopes. The 
radioligand or radiopharmaceutical drug is used as molecular probe to visualize 
and measure biochemical processes in vivo in a non invasively way. When the 
radioisotope decays, the positron annihilates with a tissue electron and generates 
two photons with a 511 keV energy which are detectied by the tomograph. The two 
photons are simultaneously emitted in the same direction but with contrary verse. 
Their flight direction is measured using detectors. The most used radioisotopes in 
PET are Carbon-11 (11C), Nitrogen-13 (13N), Oxygen-15 (15O) which replace a 
stable atom within a pharmaceutical molecule without changes in biochemical form. 
A particular case is Fluorine-18 (18F). Fluorine-18 has chemical properties similar to 
those of Hydrogen (H) which can be replaced in many natural molecules as 
aminoacids, carbohydrates, lipids and in many drugs permitting the analysis of 
metabolic function as for example glucose metabolism. Other isotopes like Gallium-
68 and Copper-64 are not present in natural compounds. For their chemical 
properties or half-life are of particular interest for the labelling of biotechnological 
molecules like peptide (Ga-68) or antibody (Cu-64). 
 
1.2.1. Physical principles  
 
1.2.1.1. Acquisition of events in coincidence  
In the positron emission tomography, a decay event can be registered when the 
two photons are simultaneously detected inside the field of view, FOV, i.e. in the 
spatial portion sampled by tomograph. The coincidence technique requires that the 
coincident photons, detected by two different detectors, at the same time fall in a 
small time window (coincidence window) of about 10 nanoseconds. A line of 
response (LOR,) obtained by the straight line which connects the detection points 
of the two photons, is associated at each coincidence event. The source which 
generated the coincidence is on a point of this straight line. When the LOR is 
identified, the event is added at the just acquired events for that precise response 
line and the obtained sum is registered in the system memory. The final value of 
the acquired events for a LOR is connected at the activity of radionuclide along the 
straight line[1]. In the practice, it is impossible sampling all infinitive LOR of 
detected events. At each LOR is associated a volume of response (VOR) and the 
number of counts of a LOR is connected at the sum of decay events within the 
VOR. 
A LOR is identified by 4 coordinates: r, φ, ν, s. 
r is the shortest distance between the LOR and the centre of tomograph in the 
transaxial axis; 
φ e ν are the angles between the LOR and y system axis in transaxial and axial 
axis respectively; 
in a definite number of fractions called tilt. 
A coincidence event is registered if the following conditions are satisfied:  
- two photons are detected within the coincidence time window;  
- the decoded line of response is in the field of view of tomograph;  
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- ν angle of the line of response is smaller than the angle of acceptance of 
the tomograph;  
- the energy of the two detected photons is included in the energetic window 
of the tomograph, which has an inferior energetic threshold  to reduce the 
number of acquired events of scatter and a superior energetic threshold to 
remove possible pile-up problems and contaminations problems due to 
environmental radioactivity. 
The events that satisfy these requisites are the prompts (P). The above requisites 
are not sufficient to remove all undesired events. The number of prompts is the 
results of the sum of the number of true events (T), random events (R), scatter 
events (S):  
 
                                   P = T + R + S. 
  
A scatter coincidence occurs when one or both of photons interact with tissue 
before the arrival to the detector. Consequently, a wrong LOR is assigned to the 
event. A decreased contrast and an inaccurate quantification of the final image are 
the result.  
A random coincidence occurs when two atoms decay in the same moment. In this 
case two not correlated photons can be detected in the same coincidence window. 
An error of localization of decay is the result. A method to estimate the number of 
random events is the method of delayed window. A delayed coincidence window 
has the same duration of a classic coincidence window but the time of coincidence 
is five times delayed. The events detected in this window are only due to random 
coincidences and they can be used to estimate random events of the first window. 
Multiple events have analogous origin to random events: three photons of two 
different annihilations are detected in the same coincidence window. The 
frequency of detection of multiple events is a function of the count frequency. 
 
1.2.1.2. Spatial resolution 
The emission positron physics calls for some limits to spatial resolution: 
 
- the path of positron before annihilation because the aim of positron 
emission tomography is that of mapping the distribution of positron emitters 
and not that of annihilation points;    
- the positron can not have all its energy dissipate. The positron has a 
residual moment and consequently, for the preservation of the moment, 
the two photons are not emitted to 180°. Supposing that the two photons 
are emitted to 180°, an error in the assignment of LOR is committed which 
causes a degradation of spatial resolution.  
 
The resolution is of millimetres order because the site of annihilation of positron, 
which is visualized using positron emission tomography, can be localized at various 
millimetres of distance from the origin site of the positron itself. 
These limits are intrinsic to the physics of PET. The dimension, the distance and 
the form of detectors mostly influence the degradation of spatial resolution.  
Nowadays, the spatial resolution of PET is in the best of cases 5 mm for clinical 
tomograph and 1,5 mm for tomograph for preclinical studies characterized by a 
smaller field of view. 
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1.2.1.3. Detector system 
Physical configuration of PET tomographs is focused to maximize the detection of 
the coincident events and to minimize that of noise events. 
PET detectors are inorganic scintillators with high atomic number coupled with a 
series of photomultiplicators (PMT). The first scintillators, developed in the 70s, 
were crystals of Sodium Iodure activated with Thallium (NaI(Tl)). Due to the low 
density of Sodium Iodure, the detection of the 511 Kev annihilation photons was 
difficult. In the last years, Bismuth Germanate (BGO) was introduced which, thanks 
to  its high density, allows an improvement of sensitivity but it also causes a 
decrease of energetic resolution.  
Nowadays, fast scintillators are used including Gadolinium Orthosilicate (GSO) and 
Luthetium Orthosilicate (LSO), both with the presence of Cerius. 
These scintillators significantly have improved the quality of the scanner used for 
clinical imaging. 
Using these fast scintillators, it is possible decrease the window of coincidence for 
decreasing the detection of random events. 
These scintillators also have a higher photoelectric fraction which allows a better 
energetic resolution and a subdivision of detection blocks into smaller crystals for 
improving spatial resolution [2]. 
 
1.2.1.4. Images acquisition and reconstruction  
Positron Emission Tomography is intrinsically a 3D imaging modality but it can 
work also in 2D modality. The 2D acquisition modality is based on Lead or 
Tungsten septum which allow to define the acquisition level limiting oblique 
acquisitions. 
The levels can be generated in different ways depending on number of levels, 
spatial resolution in axial direction and efficiency of detection per level.  
In 3D modality, the septum are not present and all possible LOR with an angle 
inferior to that of acceptance and localized between the rings are accepted. This 
configuration leads to an increase of sensitivity because the number of response 
lines, along it is possible to perform the acquisition, increases and the shadow 
projected on detectors disappears. 3D modality includes a higher number of rare 
events detected but on the other hand, a higher fraction of random and scatter 
events in acquired coincidences. 
The events are acquired in matrix of sinograms, in which each row of matrix 
represents parallel projection p (s φ) of the distribution of radioactivity in the subject 
with a specific angle(φ) and axial position (z) (Fig.1). 
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Starting to sinograms, the reconstruction of image is performed by applying 
algorithms of reconstruction. The most used algorithm is the Filter Back Projection 
(FBP) which originally was developed for x-rays tomography. 
The simplicity of implementation and the elevated computational efficiency are the 
most successful characteristics of this technique.  
In the 3D acquisition, FBP algorithm is generalized in a three-dimensional space 
and the vlume g (x,y,z) is oversampled by the integrals of plane p (s,r,φ,ν).  
FBP algorithm is based on a ideal model and it operates only in the reconstruction 
of images with low noise such as cerebral acquisition but not in total body 
acquisition. 
In presence of high background noise, the FBP algorithm amplify the high frequency 
components of the data of projection and thus the statistic noise.  
In the use of it, in a non ideal case, filters for noise attenuation and a correction for 
attenuation are necessary. 
Other reconstruction algorithms exist. They are based on iterative techniques which 
directly incorporates the stochastic nature of emission process and photons 
detection and important physical characteristic of source-detector system (i.e. 
attenuation, detection geometry, presence of scatter or random coincidences). 
These algorithms are based on the research of the convergence solution of an 
equation system, through a series of subsequent iterations starting from a first 
approximate solution. 
In each iteration, the profiles obtained by retroprojecting are corrected through the 
comparison to measured projection. 
These techniques, including FORE (Fourier Rebinning) and OSEM (ordered-subset 
expectation maximization), allow more accurate reconstructions but they are 
characterized by longer reconstruction time in comparison to FBP [2]. 
For the data reconstruction, FBP algorithm woks on a limited angle in axial direction; 
thus the fraction of accepted data by software varies between 15-50% for each 
Fig.1 Townsend DW. Physical principles and technology of clinical PET 
imaging. Annals of the Academy of Medicine 2004;33(2):133-45. 
On the left, injection of bradiopharmaceutical and acquisition of a pair of 
annihilation photons in a PET scan; sinograms collection in which each 
element of sinogram presents the number of annihilations in a specific 
projection direction; finally the whole body image. 
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acquisition. To reconstruct all events without a decrease of resolution, Expectation 
Maximization (EM) algorithm is used for reconstruction of images [2]. 
EM algorithm is a general iterative method for the resolution of problems of 
evaluation, in which a part of observations misses or is censured. The centre of the 
iterative reconstruction is the matrix of probability i.e. a scattered matrix which 
needs long time for the computation. In fact digital images are made of matrix. 
The dimension of this matrix is obtained by the product of the number of detected 
LOR and the number of voxel in the Field Of View; it varies between hundreds of 
Gigabyte and tens of Terabyte. 
The matrix can not be uploaded during algorithm calculation but it may be loaded 
on-line during the iteration. 
Using all symmetries, the dimension of space occupied by matrix is reduced for a 
total factor of 80 value. Scattered matrix properties are used: element value is 0 
when the voxel lies out the LOR and only non-zero values are stored. 
When sinograms parameters and the voxel of the FPV are fixed, before 
reconstruction starts, only non-zero values of probability and their coordinates in the 
original LOR are stored on disk. 
During iteration, the original LOR is analyzed and the index correspondent to the 
value are calculated.  
EM iteration needs 3-15 minutes analysis. The time of calculation depends on the 
parameters: smaller voxel need more time analysis.  
This type of reconstruction performs spatial resolution and it is used for 
reconstructing imaging in dedicated tomograph for small animal such as  YAP-
(S)PET. 
 
1.2.2. PET and preclinical imaging  
 
For many years, PET molecular imaging was focused to clinical studies. Preclinical 
activities were addressed to develop and characterize new ligands to successively 
apply in clinical studies. 
The recent availability of dedicated small animal tomographs with suitable 
sensitivity and spatial resolution together to the availability of appropriate animal 
models of disease has enabled the use of this method in preclinical research. 
This technique offers numerous advantages: 
 
1. extensive field of applicability. Many ligands can be labelled with positron 
emitted isotopes without changes in the biological activity; 
2. scarce invasivity. The radiopharmaceuticals are administered in microdose 
(<1/100 of active dose); 
3. tomographic acquisition; 
4. preclinical results can be translated in clinic; 
5. studies were performed in vivo as in clinic. 
 
Animal PET allows to reduce the time of screening and the development of new 
radiotracers to apply in oncologic field and neurodegenerative field and in the study 
in vivo of specific molecular target in preclinical model. 
Finally, the use of animal PET allows to reduce the number of animals to employ in 
the experiments without decrease of information in comparison to the other 
methods. 
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In addition, techniques for the labelling of antibodies or antibody fragments to apply 
in preclinical tumour model and techniques for the labelling of probes to use in 
gene reporter systems for studying genetic expression have been developed [3].  
 
1.2.3. Tomographs for small animals  
 
Nowadays, several types of tomographs dedicated to small animals have been 
developed. They have different configurations and physic characteristics. For the 
performance of a clinical scanner, spatial resolution, sensitivity, counts efficiency, 
image quality and corrections accuracy on total body images are the parameters of 
reference.  
In consideration of difference in dimension between clinical and preclinical 
tomographs, these parameters are not completely applied. For the calibrations, a 
not-standardized method, using “phantoms”, is applied [4].  
The main commercial PET systems for small animal are microPET R4 and 
microPET P4 (Concorde Microsystem Inc, USA); HIDAC and Quad-HIDAC animal 
PET system (Oxford Positron System, UK), whose characteristics are summarized 
in table 1. The most recent system is Triumph pre-clinical system (GE Healthcare, 
USA), a fully integrated molecular imaging system which combines PET, SPECT 
and CT. PET unit, thanks to scintillators individually coupled to Avalanche Photo 
Diode (APD) detectors, reaches a spatial resolution similar to the limit of geometric 
resolution of crystals (about 0.9 mm FWHM). The high energy resolution (4.5% at 
140keV) of the Cadmium Zinc Telluride (CZT) detector of the SPECT unit reduces 
radiation scatter, enables simultaneous multi-isotope imaging and allows a high 
resolution (<1mm). The CT X-O unit allows a 100 µm spatial resolution coupled 
with sub-minute whole body acquisition time.  
 
 
 
 
 
 
 
 
 
MicroPET system is based on a detection system with scintillators with high density 
and high resolution LSO crystals coupled with photomoltiplicators sensitive to the 
position. HIDAC animal PET system is based on high density avalanche chamber 
detector modules consisting of argon-flooded multiwire proportional chambers 
(MWPC) applied with conversion plates made up of laminated layers of lead and 
insulating sheets, drilled with a dense matrix of small holes [4].  
Tab.1 Weber and Bauer. European Journal of Nuclear Medicine and Molecular 
Imaging. 2004;31(11):1545-55. 
Animal PET charactetistics. FORE Fourier Rebinning, FBP Filtered Back 
Projection, OSEM Ordered Subset EM, EM Expectation Maximization, ns not 
specified. 
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HIDAC animal PET system has a field of view similar to that of MicroPET system 
(10-17cm in transaxial direction 10-12cm respectively) but a higher spatial 
resolution (0,9-1,2 mm in comparison to 1,8 mm). 
1.2.3.1 YAP-(S)PET II 
Studies were performed with YAP-(S)PET II (ISE srl, Pisa, Italy) (Fig2). The 
instrument is composed by four detectors positioned on a rotatory gantry in a 
planar/parallel configuration in way that opposite detectors are in temporal 
coincidence. A photomultiplier is directly coupled with each detector block to 
reduce decoding errors. The scintillators are composed by YAlO3:Ce (YAP:Ce) 
crystals. The machine is equipped by a laser which facilitates animal positioning 
and by a motorized bed which is controlled by a computer. Animals are acquired in 
3D modality and images are reconstructed with EM (Expectation Maximization) 
algorithm. EM reconstruction improves spatial resolution: from 2.5 mm obtained by 
FBP (Filter Back Projection) reconstruction to 1.7 mm that is the best possible 
result with 15 minutes per iteration. Signal to noise ratio (SNR) decreases with the 
number of iterations but it is better in comparison to SNR value obtained with FBP, 
thanks to the use of all data.  
This instrument can work in combined PET-SPECT modality without changing the 
acquisition system. It can be also coupled with a CT unit. The machine has a 
spatial resolution of about 1.75 mm comparable to that of the most advanced 
instrument (1.5 mm), a sensitivity of 2% total counts and a 4x4x4 field of view in 
coronal, axial and transaxial directions [5].  
 
 
 
 
 
Fig.2 YAP-(S)PET II (ISE s.r.l.; Pisa, Italy)  
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1.2.4. PET application 
 
PET molecular imaging allows to identify and study specific biological alterations 
which are present in the beginning phase of disease and to monitor disease 
progression in a non-invasively way. 
The possibility to correlate biological data with specific symptomatologycal cluster in 
the initial phase of disease and during its progression is very important for the 
identification of specific subpopulation which are present within a clinical class and 
for the development and the monitoring of innovative therapies.  
One of the most used radiotracers is an analogue of glucose labelled with F-18, the 
2-[F-18]Fluorine-2-deoxy-D-glucose ([18F]-FDG). It is used both in clinical and in 
preclinical research. This radiotracer is uptaked by cells through glucose 
transporters and it is phosphorylated in position 6 by hexokinase. [18F]FDG does not 
have hydroxyl group in position 2; after phosphorylation it can not continue 
glycolysis pathway and it is entrapped within cell. [18F]FDG is the most used tracer 
to imaging heart, brain and tumour diseases. 
In the brain, glucose is the main metabolite for ATP synthesis and during a disease 
its consumption decreases, thus this radiotracer has allowed to study many 
neurodegenerative pathologies including cortical dementia, Alzheimer’s disease and 
to differentiate patients affected by dementia from the normal effects of aging or 
from the presence of depressive disease [6,7]. 
In the heart tissue, using [18F]FDG is possible to distinguish ipoperfused but vital 
areas from ipoperfused necrotic area. 
In oncology, neoplastic tissues showed a higher consumption of glucose due to the 
progressive lost of the tricarboxylic acid cycle and the consequent activation of the 
pentose phosphate pathway. Pentose phosphate pathway produces the carbonic 
skeletons for the synthesis of DNA and RNA due to the high cell proliferation.  
Using [18F]FDG-PET is possible to identify metabolic alterations before anatomical 
alterations are present, thus this technique has a higher sensitivity in comparison to 
CT in the diagnosis of some types of tumours including non-small cell lung 
carcinoma, colon carcinoma, breast carcinoma, melanoma and head-neck tumours 
[8].  
The development of total body PET analysis has been important to detect the 
presence of primary recurrence lesions. In addition it has allowed to identify the 
presence of secondary lesions (metastases) and to improve therapeutic protocols 
monitoring the response to different types, doses and time of treatment [4]. 
The information obtained using PET analysis, summed to anatomical information 
obtained by CT and MRI can: 
 
1. discriminate benign to malign lesions, 
2. identify biological changes of tumour from primary stage to its progression, 
3. visualize all boy organs to detect primary tumours, metastases and their 
extension. In this way it is possible to detect also asymptomatic diseases 
4. discriminate malign tissues from, necrotic ones, oedema, scared tissues. 
5. monitor therapy response and to improve therapeutic protocol.  
 
[18F]FDG can be also used to visualize inflammatory process, this application will 
be discussed in a following paragraph. 
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Successively, many other radiopharmaceuticals have been developed to visualize 
and monitor specific metabolism and processes. 
[11C]Choline allows to monitor the metabolism of phospholipids of membrane. 
Tumour cells showed an increase of phosphatidylcholine due to an increase of 
choline kinase activity to sustain tumour growth. This molecule was used in brain, 
lung and bladder cancer but its main application is in prostate cancer because of its 
localization, near bladder, [18F]FDG use is impaired. [11C]PK11195 and analogue 
molecules of ligands of peripheral benzodiazepine receptors allow to monitor 
neuroinflammatory disorders such as Alzheimer disease and multiple sclerosis. 
[18F]FLT (Fluorine-levo-thymidine) is a specific marker of cell proliferation and the 
most important field of application of FLT is lung cancer.  
Another important process that can be monitored using PET imaging is tumour 
hypoxia which will be extensively discussed in the next paragraphs of the thesis.  
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1.3. Tumour and hypoxia 
 
Many solid tumours as breast, cervical, head-neck, prostate, colon, lung cancer and 
melanoma are characterized by the presence of areas of hypoxic tissue which are 
due to a lack of equilibrium between the pO2 supply to the cell and the cellular pO2 
consumption rate [9]. Hypoxia is known to be a negative prognostic factor both for 
the answer to pharmacological and radiant therapy and for disease progression and 
tumour invasiveness. In fact, since the half of the last century hypoxia was 
described as cause of radiotherapy failure in solid tumours [9,10]. More recently, 
tumour hypoxia was associated to decrease the efficacy of certain cytotoxic drugs 
including cyclophosphamide, carboplatin, carmustine and melphalan [9]. Finally the 
hypoxic microenvironment promotes tumour progression in particular local invasion 
and distant metastasis.  
Hypoxic stress can lead to two consequences to tumoural cells. From one side, it 
induces cellular growth stasis or impairment through modulations of the cellular 
pathways; from the other side, it promotes tumour propagation by helping cells to 
adapt to nutritive deprivation by facilitating cellular proliferation, local invasion and 
metastatic spread [9]. The first phenomena could explain the delayed recurrences, 
dormant micrometastasis and growth retardation observed in large tumour masses 
[9]. 
Hypoxia stimulates the transcription of glycolytic enzymes (hexokinase), of glucose 
transporters (GLUT-1 and GLUT-3), of angiogenetic molecules, of growth factors 
(VEGF) and of enzymes and proteins involved in the tumour spread. A lot of these 
factors are controlled by hypoxia inducible factor called HIF-1 [9,11].  
For these reasons the study of methods and instruments which permit identification 
and localization of hypoxic areas has a particular interest in clinical diagnostics. 
 
1.3.1. Pathogenesis of tumour hypoxia 
 
Hypoxic areas are the result of a disequilibrium between oxygen (O2) supply and 
consumption rate.  
Many factors can cause hypoxia but most of which are perfusion- or diffusion-
related. 
Perfusion-related (acute) hypoxia is caused by a sudden inadequate blood flow in 
tissue [9]. The neo-vases which grow within tumoural masses frequently have 
severe structural and functional abnormalities, such as a disorganized vascular 
network which cause a sudden and complete reduction in blood flow [9,12]. The 
phenomena is often transient. 
In diffusion-related (chronic) hypoxia, the growth of the tumour mass itself cause an 
increase of distance from blood vessels and cells that are exposed to a gradually 
decreasing levels of oxygen [9,12] (Fig.3) 
 
 
 
 13 
 
 
 
 
 
 
1.3.2. HIF 
 
1.3.2.1. HIF structures 
The most important regulator of the cellular response to hypoxic stress is hypoxia-
inducible factor 1 (HIF-1). This factor helps cell to adapt to oxygen deprivation by 
regulating the expression of genes that are involved in many cellular processes as 
glucose uptake, metabolism, angiogenesis, erythropoiesis, cell proliferation and 
apoptosis [10]. 
HIF-1, is an αβ-heterodimeric transcription factor, consists of a constitutively 
expressed HIF-1β subunit also known as ARNT (arylhydrocarbon receptor nuclear 
translocator) and a oxygen-sensitive alpha subunit (HIF-1α). Three alpha HIF 
subunits have been characterized. HIF-1α contains four distinct domains including a 
bHLH domain (basic helix-loop-helix) for DNA binding and dimerization, a PAS 
domain (PER-ARNT-SIM family) for dimerization and target gene specificity, an 
oxygen-dependent degradation domain (ODD) required for degradation by the 
ubiquitin-proteasome pathway, and two transactivation domains located in the C-
terminal portion of the protein (Fig.4). It is ubiquitously expressed and induces the 
expression of many hypoxia-inducible genes [10].  
HIF-2α is structurally similar to HIF-1α and contains bHLH, PAS and ODD motifs 
with 85, 70 and 70% amino-acid sequence omology to HIF-1α. It heterodimerizes 
with ARNT and can induce gene expression. In contrast to HIF-1α, HIF2α 
expression is restricted to specific cell types that include endothelial cells, glial cells, 
type II pneumocytes, cardiomyocytes, fibroblasts of the kidney, interstitial cells of 
the pancreas and duodenum and hepatocytes [10]. 
The third alpha member HIF-3α has an amino-acid sequence with 57% and 53% of 
identity to HIF-1α and HIF-2α respectively and an ODD domain 61% similar in 
sequence to the HIF-1α ODD domain. It can dimerizes with the subunit beta and 
bind to the hypoxia response elements (HREs) in vitro. The mRNA can be detected 
Fig.3 Stewart et al. British Journal of Urology International 2009;105:8-13. 
Schematic representation of acute and cronic hypoxia within a solid tumor 
deposit. 
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in many tissues including thymus, lung, brain, heart, kidney, liver, eye and brain 
[10]. 
ARNT or HIF beta subunit is the general binding partner for all bHLH/PAS family 
members. Similar to HIF-α subunits, ARNT contains bHLH, PAS, and a 
transactivation domain (Fig.4). However, ARNT lacks an ODD domain and is 
therefore constitutively expressed in all tissues under aerobic conditions [10]. 
Another HIF-β subunit exists and it can also heterodimerize with HIF-alpha proteins, 
ARNT2. The two proteins are very similar but the expression patters are different. In 
particular, whereas Arnt mRNA is ubiquitously expressed, Arnt2 expression is 
restricted to the brain and kidney in adult tissues. 
 
 
 
 
  
 
 
 
 
1.3.2.2. Role of HIF in hypoxia 
The synthesis of HIF-1α is regulated by activation of the phosphatidylinositol 3-
kinase (PI3K) and mitogen-activated protein kinase (MAPK) pathways. These 
pathways can be activated by signalling via receptor tyrosine kinases, non-receptor 
tyrosine kinases or G-protein-coupled receptors [13]. 
In condition of normoxia (O2) and in presence of Fe2+, 2-oxoglutarate (2-OG) and 
ascorbate, HIF-1α is hydroxylated by proline hydroxylases (PHD1, 2 and 3) at level 
of Proline (Pro)-402 and -564. Hydroxilated HIF-1α(OH) is recognized by pVHL (the 
product of the von Hippel-Lindau tumour suppressor gene) which, together with a 
multisubunit ubiquitin ligase complex, tags HIF-1α with polyubiquitin. The formed 
complex is recognized by the proteosome and degradated. Oxygen also regulates 
the interaction of HIF-1α with transcriptional co-activators. The factor inhibiting HIF-
1 (FIH-1) hydroxylates asparagine (Asn)-803 in the transactivation domain blocking 
the binding of p300 and CBP and therefore inhibiting HIF-1-mediated genes 
transcription. In hypoxic condition, proline hydroxylases can not hydroxylate HIF-1α 
and the binding of VHL to HIF-1α and the successively degradation are inhibited. 
HIF-1α accumulates and translocates in the nucleus where dimerizes with the 
subunit β. The heterodimer binds to hypoxia-response elements (HREs) within the 
Fig.4 Rankin and Giaccia. Cell Death and Differentiation 2008;15:678-85. 
Schematic representation of HIF family member protein domains. 
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promoters of target genes and recruits transcriptional co-activators such as 
p300/CBP for full transcriptional activity (Fig.5). The same mechanism is valid also 
for HIF-2α and HIF-3α [12]. 
 
 
 
 
 
 
 
 
 
HIF-1α expression is also induced from pathways activated by growth factor 
signals. In comparison to the increase of HIF-1α induced by hypoxia, growth factor 
signals stimulate HIF-1α expression in a cell-type specific manner [13]. The 
synthesis is performed through activation of phosphatidylinositol 3-kinase (PIK3) or 
mitogen-activated protein (MAPK) pathways as illustrated in figure 6. The effect of 
growth factor signalling is an increased of expression of HIF-1α protein. In this 
condition of over-expression of HIF-1 protein, FIH-1 could became limiting and the 
number of HIF-1α or HIF-2α transcriptionally active could increase. HIF-1 could 
transcript growth factor gene initiating an autocrine signalling pathway that in cancer 
cells could be crucial for tumour progression. 
 
 
Fig.5 Stewart et al. BJU International 2010;105:8-13.  
Representation  of the mechanism of action of HIF-1α in presence (A) or 
absence (B) of oxygen. 
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HIF promotes the transcription of many genes involved in key steps of 
tumorigenesis including angiogenesis, metabolism, proliferation, metastasis and 
differentiation. 
Angiogenesis is very important for tumour progression to supply oxygen and 
nutriments. HIF can activate the expression of a number of pro-angiogenic factors 
including VEGF, VEGF receptors FLT-1 and FLK-1, plasminogen activator inhibitor-
1 (PAI-1), angiopoietins (ANG-1 and -2), platelet-derived growth factor B (PDGF-B) 
and matrix metalloproteinases MMP-2 and MMP-9. VEGF is expressed in a large 
number of human tumours.  
HIF directly regulates genes involved in glycolytic metabolism including glucose 
transporters GLUT-1 and GLUT-3, glycolytic enzymes like hexokinase 1 and 3, 
lactate production and pyruvate metabolism. 
HIF family controls cellular proliferation through modulation of C-Myc activity. 
Fig.6 Semenza. Nature Reviews Cancer 2003;3:721-732.  
Representation of HIF-1α synthesis via growth factor signalling pathways. 
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The presence of metastasis is a negative prognostic factor in tumour pathogenesis. 
The metastatic process is characterized by several steps: cell invasion, 
intravasation, extravasation and proliferation. HIF actives and promotes metastasis 
through the activation of many factors including: E-cadherin that regulates cell-cell 
adhesion; extracellular matrix protein LOX (lysyl oxidase) that is involved in 
extracellular matrix formation; CXCR4 (C-X-C chemokine receptor type 4) and its 
ligand SDF-1 (stromal derived factor 1) that play a role in the directional migration of 
metastatic tumour cells. 
 
1.3.3. Glycolysis and respiration 
 
Altered glucose metabolism is a characteristic of invasive cancers. Otto Warburg 
since 1924 noticed that cancer cells preferentially converted glucose into lactic acid 
instead of pyruvate even in presence of sufficient oxygen, for this reason “Warburg 
Effect” is also called aerobic glycolysis. Warburg hypothesized that this 
phenomenon was due to an impairment of mitochondrial functionality but many 
studies deny this hypothesis [14,15].    
Aerobic glycolysis seems a disadvantageous method to create energy. In fact, it 
generates only 2 ATPs per molecule of glucose, whereas oxidative phosphorilation 
generates up to 36 ATPs molecules upon complete oxidation of one glucose 
molecule. Unicellular organisms such as microbes change their metabolic 
phenotype in relationship with environmental conditions. In presence of abundant 
nutrients, they quickly replicate growing by fermentation of glucose into a small 
organic molecule such as ethanol. When nutrients are scarse, cell stops biomass 
production and converts metabolism to extract the maximum possible energy from 
the available supply to survive the starvation period. In a similar way, multicellular 
organism adopts a proliferative metabolism in presence of growth signals and a 
quiescent metabolism in absence of growth signals [16] (Fig.7). Cancer cells have 
genetic mutations in growth pathway that overcome this control system. Proliferating 
tumour cells seem to use a less efficient metabolism which is anyway able to satisfy 
the need of the cell. Glucose and glutamine supply most of the carbon, nitrogen, 
free energy and reduced equivalents necessary to support cell growth and division. 
Glucose can be converted to macromolecular precursors such as acetyl-CoA for 
fatty acids, glycolytic intermediates for nonessential aminoacids and ribose for 
nucleotides. For example, the pentose phosphate pathway (PPP) uses glucose-6-
phosphate to generate NADPH which contributes to fatty acid synthesis and, 
together with ribose-5-phosphate, to nucleotide synthesis (Fig.8). In addition, 
glutamine is used by proliferating tumour cells to generate α-ketoglutarate which 
can be metabolized through the tricarboxylic acid (TCA) cycle to generate 
oxaloacetate (OAA) [17]. Glutaminolysis can produce NADPH as energy source via 
the activity of NADP+-specific malate dehidrogenase with production of lactate as 
end-product. 
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Mutations in metabolic enzymes become very important to carcinogenesis in fact 
normal cells need exogenous stimulation to proliferate whereas in tumour cells 
genetic alterations support cell growth in every condition. The most important 
regulators identified are the members of PI3K/Akt/mTOR pathway, HIF-1α and c-
myc. Akt increases the expression of glucose transporters and glycolytic enzymes 
favoring glucose to lactate metabolic pathway and Warburg effect. Genetic 
alterations in PI3K and PTEN (a negative regulator of PI3K) lead to a chronic 
activation of Akt. HIF-1α is stabilized by the activation of the PI3K/Akt/mTOR 
pathway. HIF-1α increases the expression of glucose transporters, glycolytic 
enzymes, PDK and LDH-A. c-Myc is an oncogenic factor and also stimulates the 
expression of glycolyitic enzymes and genes involved in mitochondrial biogenesis. 
Lactate may be also seen as a source of energy in particular conditions. Sonveaux 
et al. demonstrated the presence of a metabolic symbiosis between hypoxic and 
aerobic tumour cells [18]. Hypoxic cells produced lactate which was used as 
principal source of energy by aerobic cells. Aerobic tumour cells, which were 
localized near blood vessels, prefered using lactate over glucose in oxidative 
metabolism and in this way, glucose could be available for hypoxic cells for aerobic 
glycolysis. Sonveaux et al. identified, in mouse and human tumours, MCT1 
(monocarboxylate transporter 1) as the major transporter ensuring lactate uptake by 
oxidative tumour cells and MCT4 (monocarboxylate transporter 4) as a hypoxia-
induced transporter involved in the removal of lactate from glycolytic cells [17,18] 
Fig.7 Vander Heiden et al. Science 2009;324:1029-1033. 
 Microbes and cells from multicellular organisms have a similar 
metabolism under similar environmental conditions. Proliferative cells 
metabolize glucose or sugar through glycolysis excreting large amounts 
of carbon in the form of ethanol, lactate or other organic acids. In lack of 
nutrients, unicellular organism use a oxidative metabolism to starve 
energy as do cells in multicellular organism in absence of growth 
signals. 
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(Fig.9). Moreover, MCT1 was found in the tumour cell population located in 
vascularised tumour area whereas MCT4 was consistently concentrated in hypoxic 
regions. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The upregulation of glycolysis and the consequent production of lactate lead to a 
decrease of extracellular pH. Normal cells death, due to a prolonged exposition to 
an acidic microenvironment, is induced for necrosis or apoptosis through p53- and 
caspase-3-dependent mechanism. Tumoural cells adapt to extracellular acidosis 
through resistance to apoptosis or upregulation of membrane transporters to 
maintain normal intracellular pH. Acidosis is crucial for the development of invasive 
cancer. First, acidosis alters the local environment permitting the survival of 
tumoural cells and causing the death of other populations. Second, acidification of 
the microenvironment facilitates invasion both through destruction of adjacent 
normal populations and through acid-induced degradation of the extracellular matrix 
(ECM) and promotion of angiogenesis [19].  
Gatenby and Gillies suggest that acidosis itself can be mutagenic and clastogenic, 
possibly through inhibition of DNA repair and can lead to both inhibition of gap-
Fig.8 Feron. Radiotherapy and Oncology 2009; 
doi:10.1016/j.radonc.2009.06.025. 
 Glycolysis in proliferating cells. Glycolytic flux generates ATP and biosynthetic 
precursors in the cytosol. Pyruvate is converted into lactate by lactate 
dehydrogenase A (LDH-A). Pyruvate dehidrogenase kinase (PDK) blocks the 
activation of mithocondrial pyruvate dehydrogenase (PDH), limiting the pyruvate 
conversion into acetyl-CoA and further feeding the TCA cycle. Hypoxia-
inducible factor 1alpha (HIF-1alpha) stimulates the expression of LDH-A and 
PDK and moreover the glycolytic flux by increasing the expression of glucose 
transporters and/or glycolytic enzymes as well as Akt and c-Myc. C-Myc also 
stimulates LDH-A expression. 
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junction conductance and to spontaneous transformation of normal diploid 
fibroblasts. In this way the basement membrane can be breached and the tumour 
become vascular both by the pre-existing vessels within the stroma and by the new 
vessels growth directly into the tumour mass. Tumour cells can come out and 
invade other tissues. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1.3.4. Hypoxia and therapy resistance 
 
Gottwald Schwart in 1909 for the first time described the phenomenon of clinical 
radioresistance [20] but only in 1953 Gray et al. pointed toward the importance of 
tumour hypoxia as a cause of radioresistance. Now it is well established that solid 
tumours may contain oxygen-deficient hypoxic areas and that cells are 
radioresistant [21]. Moreover hypoxia also induces resistance to chemotherapy 
treatments including cyclophosphamide, carboplatin, carmustine and melfalan [22].  
Hypoxia-induced radioresistance is multifactorial. First, the presence of oxygen 
causes DNA damage through the formation of oxygen free radicals which occurs 
after the interaction of radiation with intracellular water. Well-oxygenated cell are 
three times more sensitive to x-and gamma radiation than the same cells when 
Fig.9 Feron. Radiotherapy and Oncology 2009; 
doi:10.1016/j.radonc.2009.06.025.  
Lactate metabolic symbiosis. Aerobic tumor cell is near blood 
vessel and express monocarboxylate transporter 1 (MCT1) to 
uptake lactate fro using it as principal substrate for mithocondrial 
oxidative phosphorylation. In this way, glucose is available for 
glycolysis in hypoxic tumor cells. Lactate is then secreted 
through the hypoxia-induced monocarboxylate transporter 4 
(MCT4) in the interstitial fluid. 
 21 
they are hypoxic [23]. Moreover hypoxia mediates proteomic and genomic changes 
that contribute to radioresistance as increase of heat shock proteins (HSPs) or 
increase of the number of tumour cells that can resist to apoptosis by mutating p53 
or expression of stress proteins that protect cells by the action of DNA 
topoisomerases inhibitors, including etoposide and camptotecine [24]. Finally, 
anomalous angiogenesis may interfere with the correct release of chemotherapy 
drugs. 
All these mechanisms together ensure that tumour hypoxia is a negative prognostic 
factor. In order to outcome and identify patients with a worst prognosis and/or 
patients that would benefit from appropriate treatments, in vivo measurement of 
tumour hypoxia is required. 
 
1.3.5. In vivo measurement of tissue hypoxia  
 
Tumour hypoxia is a very important biological feature and there is not a simple and 
good method to identify its presence. Imaging could be a good non-invasively way 
to visualize tumour hypoxia and select patients for the most appropriate therapy. 
Imaging could also be used to monitor the effect of re-oxigenation after 
radiotherapy.  
Nowadays, it is possible to measure hypoxia on the basis of three principles: 
 
1) Identification of gene activation and molecular activity caused by hypoxia in 
biopsy specimens. 
2) Measurement of the physical amount of oxygen in a tissue using 
polarografic electrodes. 
3) Use of radiolabelled compounds that are reduced by hypoxic cells. 
 
1.3.5.1. Biopsy specimens  
Hypoxia-inducible factor 1 (HIF-1) is responsible of the transcription of many genes 
in condition of hypoxia. The HIF-1 pathway mediates hypoxia response by 
transcription of genes involved in glucose metabolism as glucose transporters 
(GLUT) and hexokinase (HK), in angiogenesis as vascular endothelial growth factor 
(VEGF), in erythropoiesis as erythropoietin and in apoptosis as carbonic anhydrase 
IX (CAIX). All these molecules are possible target of hypoxia condition. In particular 
carbonic anhydrase IX is the most used in immunohistochemical analysis. Carbonic 
anhydrase IX favours cellular survival by promoting invasiveness and by inhibiting 
apoptosis. A further marker for hypoxia is pimonidazole which is used ex-vivo 
particularly for preclinical studies. Pimonidazole hydrochloride is a bioreductive 
chemical probe with an immunorecognizable side chain. The addition of the first 
electron during bioreductive activation is reversibly inhibited by oxygen, resulting in 
futile cycling with half-maximal p=2 of inhibition of about 3 mmHg, with complete 
inhibition occurring at about 10 mmHg [25].  
  
1.3.5.2. Polarographic electrodes 
Polarographic electrodes is the most used technique for tissue hypoxia 
determination. Oxygen probes are implanted directly into tumours to measure 
oxygen concentration. The probe has a surface of about 25 µm. A negative voltage 
is applied between the catode and the anode, the oxygen flow reaches the cathode 
where it is reduced. The electrons are captured by the cathode and the produced 
current is proportional to oxygen concentration.   
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Recently this method has been coupled with computed tomography and a 
ultrasound guide to improve the probe localization within the tumour. Three linear 
sections were analyzed and a total of 100-220 measurements were performed in 
each tumour to limit the tumour heterogeneity [26]. Lyng et al. studied the pO2 in 
tumoural tissues and compared the results with histological analysis. Measured pO2 
were consistent with the histological characteristics of tissue [26]. 
Nevertheless, the technique is very invasive for a clinical use and it cannot define 
the real extension of tumour hypoxia because the presence of oxygen within tumour 
is very heterogeneous.  
 
1.3.5.3. Imaging techniques  
Imaging method allows the visualization of tissue hypoxia in a non-invasive way and 
monitoring the extension and heterogeneity of hypoxia within the tumour. The most 
potential techniques are MRI-BOLD and PET in association with selected tracers. 
 
1.3.5.3.1. BOLD-MRI 
BOLD-MRI (Blood oxygenation level dependent-MRI) allows to obtain information 
on tissue perfusion, vascular volume and permeability and on the molecular and 
metabolic changes of tumours in cerebral studies by measuring oxyhaemoglobin 
and deoxyhaemoglobin ratio. 
BOLD-MRI contrast is affected by intrinsic tissue properties including spin-lattice 
and spin-spin relaxations as in classic MRI but also by blood flow and paramagnetic 
deoxyhaemoglobin within red blood cells. Oxyhaemoglobin is not paramagnetic. 
Deoxihaemoglobin increases the MR transverse relaxation rate (R2) of water in 
blood and surrounding tissues thus BOLD-MRI is sensitive to pO2 within tumour. 
Static tissue components include iron content (e.g. globin found in muscle) and the 
presence of fibrosis or ligamentous structures also affect the appearances of 
intrinsic susceptibility weighted images. In order to decouple the effects of flow from 
deoxyhaemoglobin and static components it is necessary to measure the T2 
relaxation rate (R2=1/T2). It is also important to remember that improving blood flow 
and vascular functioning will increase tissue oxygenation which can be seen in R2 
images. Thus BOLD-MRI images are more likely to reflect on acute tissue hypoxia 
which occurs because of transient occlusion of vessels. In contradistinction, chronic 
hypoxia is less likely to be reflected by BOLD-MRI because the red blood cells in 
vessels are too distant from the area of hypoxia. Moreover it is important that red 
blood cells are delivered to the tissue in analysis. It is important to determine the 
distribution of blood volume in tissue for correctly interpreting images [23].  
BOLD-MRI is a technique with high temporal and high spatial resolution. It is 
possible to decouple the effect of flow and deoxyhaemoglobin and demonstrate 
changes in oxygenation independent of changes in blood flow. Moreover, there is 
no need to administer a radioactive contrast. Indirect measurement of tissue pO2, 
images with low signal to noise ratio and the technical challenge of carbogen 
vasomodulation in clinical studies are the major limits. BOLD-MRI appears most 
sensitive to oxygen levels adjacent to perfused vessels [23]. 
 
1.3.5.3.2. PET 
In vivo PET imaging allows the visualization of tissue hypoxia using the oxygen-
dependent cellular retention of radiopharmaceuticals like [64Cu]ATSM and 
nitroimidazoles compounds such as [18F]FMISO and [18F]FAZA. Among 
nitroimidazoles compounds, [18F]FAZA showed the highest signal to noise ratio. 
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[18F]fluoroazomycin-arabinofuranoside ([18F]FAZA) is a nitroimidazole 
compound (Fig.10). In 1979, Chapman et al. proposed the use of nitroimidazoles 
compounds labelled with radioisotopes [27]. Nitroimidazoles enter in the cell for 
passive diffusion and undergo a selective bioreduction because of its instability. 
Nitroreductase mediates the bioreduction of nitroimidazole with formation of free 
radicals. In presence of oxygen, the anion of free radical is quickly reverted by 
oxygen in its original compound that can go out cell for passive diffusion. The 
oxidation speed depends on intracellular oxygen concentration. On the contrary, in 
hypoxic condition, the reduced compound undergoes further reduction steps which 
irreversibly entrapped the compound within the cell. Nitroso acid, hydroxylamine 
and aminic derivates are formed. The reactive fragments of imidazole ring react with 
macromolecular components of cell and, remaining entrapped, they accumulate 
within cell (Fig.11) [28].  
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.10 Piert et al. The Journal of 
Nuclear Medicine 2005;46:106-
113.  
Chemical structure of 
[18F]fluoroazomycinarabinoside 
([18F]FAZA). 
Fig.11 Takasawa M et al. Stroke. 2008 ;39 :1629-1637. 
Schematic rapresenations of binding of nitroimidazoles compounds. 
 
 24 
Piert et al. studied [18F]FAZA biodistribution in vivo in two tumour models: murine 
mammary carcinoma cells (EMT-6) and pancreatic acinar tumour cells (AR42J). In 
both tumours, at 180 min from radiotracer injection, [18F]FAZA displayed higher 
tumour to background, tumour to muscle and tumour to blood ratios due to its more 
rapid clearance from blood and non-target tissues in comparison to [18F]FMISO 
[29]. This data were confirmed also in a study by Reischl et al. where [18F]FAZA, 
[18F]FMISO and [124I]IAZA were compared in a preclinical model of human 
squamous cell carcinoma cells [30]. Sorger et al. compared the uptake of 
[18F]FAZA and [18F]FMISO in hypoxic cells in vitro and in a Walker 256 rat sarcoma 
model. In vitro [18F]FAZA indicated a reduced oxygen supply in the same 
magnitude order than [18F]FMISO. In vivo, [18F]FMISO displayed a slightly higher 
standardized uptake value (SUV) and tumour to muscle ratio compared to 
[18F]FAZA even if the elimination of the latter was faster [31]. Busk et al. verified the 
distribution of [18F]FAZA in hypoxic tumour region by comparing it to eppendorf 
electrode measurement and the hypoxia marker pimonidazole and it was proved to 
be consistent with tumour hypoxia [32]. Successively, Busk et al. compared the in 
vitro the cellular retention of [18F]FDG and [18F]FAZA in hypoxic condition and 
tested tracer distribution between hypoxic and non-hypoxic areas in different mice 
xenograft. The in vitro and in vivo experiments indicated that [18F]FAZA is an 
excellent marker for tumour hypoxia whereas [18F]FDG is not [33]. 
In clinic, the role of [18F]FAZA was evaluated in two studies with patients with head 
and neck cancer. A study concluded that [18F]FAZA-PET imaging was a feasible 
and adequate method for imaging tumour hypoxia [34]. The other one concluded 
that [18F]FAZA-PET imaging may be used for planning radiation treatment and 
intensity-modulated radiotherapy [35]. 
Among nitroimidazoles compounds, [18F]FAZA displayed the highest signal to 
noise ratio. 
Another promising hypoxia marker for PET is [64Cu]diacetyl-bis(N4-
methylthiosemicarbazone) ([64Cu]ATSM) (Fig12) [36]. [64Cu]ATSM has small 
molecular weight and high cell membrane permeability and thus it can diffuse 
easily from bloodstream to surrounding cells. Preclinical studies indicate that 
[64Cu]ATSM preferentially accumulates in tumour cells and more rapidly in hypoxic 
cells compared to well oxygenated cells [37-39]. Clinical studies on [64Cu]ATSM 
showed an inverse correlation between the level of radiotracer uptake in tumours 
and clinical outcome in patients with non-small cell lung cancer and cervical 
carcinoma [40,41]. Despite these promising data and studies, the exact trapping 
mechanism in hypoxic cells remains uncertain. Three different mechanisms were 
proposed. The first mechanism was proposed by Fujibayashi in 1997: Cu(II)-ATSM 
is reduced to Cu(I) in hypoxic cells, then it rapidly dissociates remaining entrapped 
within cell (Fig.13) [36]. Dearling et al. suggested than Cu(II)-ATSM reduction 
occurs in all cells independent of oxygen levels. In presence of oxygen, Cu(I)-
ATSM is reoxidized to Cu(II)-ATSM and can come out cell; in absence of oxygen, 
Cu(I) dissociates from the parent compound remaining entrapped within cell 
(Fig.13) [42]. Burgman et al. suggested that after Cu(I) dissociation, copper is 
absorbed into the intracellular copper pool. Intracellular copper homeostasis is 
regulated by a complex system of membrane transporters. Ctr1 is the primary 
cellular transporter for Cu(I) whereas the two primary exporters are ATP7A 
(Menkes protein) and ATP7B (Wilson protein). These molecules are specific for 
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Cu(I) transport. The expression of these proteins is cell dependent and may be 
responsible for the different uptake of tracer in different types of cells (Fig.13) [43]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
In different studies of comparison between [18F]FDG and [64Cu]ATSM, the hypoxic 
radiotracers were not present in necrotic areas of tumour but it mainly accumulated 
at the edge of tumour whereas [18F]FDG accumulated in the inner part [44,45]. In 
clinic, numerous studies were performed using Cu-60 which has a short life time 
(23.7min) in order to demonstrate the feasibility of using Cu-ATSM to identify 
hypoxic areas in tumours, [40,41]. In a recent work, Lewis et al. compared 
[60Cu]ATSM and [64Cu]ATSM (half time: 12.5 h) in patients with cervical carcinoma 
concluding that [64Cu]ATSM was a safe radiopharmaceutical and the quality of 
obtained images was high [46]. 
The half-time of Cu-64 allows to perform late studies. O’Donoghue et al. compared 
the distribution of [18F]FAZA to that of [64Cu]ATSM at early (2 after injection) and 
late time (24 after injection) in a head neck cancer mouse model and a prostate 
A B 
Fig.12 Fujibayashi et al. J Nucl 
Med. 1997;38(7):1155-60. 
Chemical structure of Cu-ATSM.  
Fig.13 Fujibayashi et al. J Nucl Med. 1997;38(7):1155-60 and Burgman et al. 
Nucl Med Biol. 2005;32:623-630  
Models for the uptake and accumulation of Cu-ATSM hypothesized by 
Fujibayashi (A) and Burgman (B). For Burgman uptake and accumulation of Cu-
ATSM are cell-dependent because also linked to intracellular Copper 
homeostasis. 
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cancer rat model. The authors observed that the distribution of [64Cu]ATSM at early 
and late time was similar to that of [18F]FAZA in the head neck tumour. On the 
contrary, in prostate tumour, the distribution of [64Cu]ATSM was different at early 
and late time and [18F]FAZA distribution was more similar to that of [64Cu]ATSM at 
early time (Fig.14) [47]. 
[18F]FAZA and [64Cu]ATSM, for their characteristics, are two very interesting 
molecules for detecting hypoxic tumour areas and planning the best therapy 
strategy. On the other hand, they need further studies to understand better the 
molecular mechanisms that regulate tumour uptake. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FaD R3327-
Fig.14  O’Donoghue J.A et al. Int. J. Radiation Oncology Biol. Phys. 
2005;61:1493–1502.  
On the left, PET images of prostatic tumour model (R3327-AT) and on the right 
PET images of head-neck tumour model (FaDu). A and B indicates two different 
animals injected with the same tumour cells. In head neck cancer model, the two 
radiopharmaceutical showed the same uptake. In prostatic tumour, [64Cu]ATSM at 
early and late showed a different uptake and late uptake is more similar to that of 
[18F]FAZA. 
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1.4. Cancer and inflammation 
 
In presence of a pathogen, organisms adopt a system of defence called immune 
response which is composed by two main mechanisms: innate immunity which 
represents the first response to an enemy and it is composed by granulocytes, 
macrophages and natural killer cells (NKc); and specific immunity which is 
successively activated through the presentation of specific molecules to 
lymphocytes T and B by the cells of innate immunity. 
The response of immunological system is regulated by a complex mechanism of 
chemical signals, based on the interaction of specific molecules as chemokines 
with their receptors. 
Immune system is naturally programmed to generate a response against tumoral 
cells. In response to this, tumour cells have created mechanisms to elide the attack 
of immune cells and in addition to use them to facilitate tumour growth and 
progression.  
For these reasons, the relationship between immune system and neoplasia is of 
particular interest. 
In the 1850s, Virchow suggested chronic inflammation as possible cause of cancer 
development. Many works have recently indicated that this inflammation participate 
or even is the cause, of many neoplasma [48,49].  
Generally, pathogens are responsible of the development of chronic inflammation 
and cancer development (helicobacter pylori on stomach cancer, herpes virus on 
cervical cancer and schistosomes on bladder cancers) [49]. Chronic inflammation 
may be also caused by the continuous actions of irritants such as asbestos, silica 
and smoke (bronchial cancers). Moreover, colonic inflammation such as that found 
in ulcerative colitis or Crohn’s disease, facilitates colorectal cancer [49]. 
Inflammatory response can facilitate tumour growth both in a direct and in a indirect 
way. Indirectly: inflammation is a strong response of immune system against a 
pathogen and it generates cellular and metabolic processes that bring to the 
production of free radicals and consequently they can bring to DNA damage. For 
this reason, inflammatory response has to have a fine control in the way that the 
damages do not exceed the benefits. 
Directly: inflammatory cells release factors that facilitate tumour maintenance. In 
particular, inflammatory cells regulate angiogenesis by angiogenic and angiostatic 
factors and matrix remodelling by metalloproteases and lytic enzymes. 
 
1.4.1. The role of macrophages  
 
Tumour is an heterogeneous mix of different cell types. It is composed by 
malignant cells, but also by many resident cell types, such as adipocytes and 
fibroblasts, and by migratory haematopoietic cells, most notably macrophages, 
neutrophils and mast cells which are the cells involved in innate immune response.  
Immune cells perform a protective role but also they can have a pro-tumour 
function. In fact macrophages are recruited to tumours by growth factors and 
chemokines which are produced by the tumour cells themselves. Clinical studies 
have shown a correlation between presence of macrophages and poor prognosis, 
in particular for breast, prostate, ovarian and cervical cancers [49].  
Macrophages originate from circulating monocytes which leave the blood flow to 
migrate in tissues (Fig.15). Macrophages are localized in the connective tissue in 
association with gastro-intestinal tract, in the lungs, along blood vessels in the liver 
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(where they are called kupffer cells) and in the spleen. The main role of 
macrophages is the phagocytosis of the pathogen. In fact they are the first cells 
that meet pathogens in the tissues. Macrophages recognize pathogens through 
receptors present on the cellular surface. The binding between the receptor and 
the molecules of pathogens leads to the internalization of the pathogen. During 
phagocytosis, macrophages produce many toxic products that help to kill the 
phagocytated microorganism such as hydrogen peroxide (H2O2), superoxide anion 
(O2-) and nitric oxide (NO) [50,51]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.15 Hussein MR. Int J Exp Pathol. 
2006;87:163-76.  
Formation of macrophages. 
They originated from haemapoietic stem cells of 
blood marrow. Monocytes from blood flow 
migrate in tissues where then formed 
macrophages. 
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The interaction between pathogen’s antigens and macrophage’s receptors actives 
macrophages and differentiates them in two subpopulations:  
 
- macrophages of type 1 (M1); 
- macrophages of type 2 (M2) or tumour associated macrophages (TAM). 
 
The activation of the two types of macrophages is regulated by a different 
expression of molecules such cytokines and chemokines. Polarized macrophages 
(M1 and M2) differ in terms of receptor expression, effector function and cytokine 
and chemokine production as it is possible to see in fig 16. [52]. 
 
 
 
 
 
 
Fig.16 Mantovani A et al. TRENDS in 
Immunology.2002;23:549-555.  
Different produced molecules by macrophage of 
type 1 or type 2. 
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Macrophages of type 1 are the responsible of the response against a pathogen 
through the phagocytosis and the production of toxic products, in fact they show a 
pro-inflammatory phenotype.  Successively, macrophages of type 2 take part in the 
interruption of the response of M1. In particular, they “clean” the areas from debris, 
repair and reconstructed the tissue which has been damaged by M1 action. 
Tumour cells exploit the capabilities of macrophages of promoting angiogenesis, 
tissue remodelling and proliferation to growth and progress. 
Tumour cells release chemotactic factors which facilitates the migration of 
macrophages of type 2 or TAMs, including Macrophages Colony Stimulating Factor 
(M-CSF) and chemokines such as MCP-1/CCL2, Macrophages Inflammatory 
Protein/CC Ligand (MIP-1α/CCL3; MIP-1β/CCL4; RANTES/CCL5; MCP-2/CCL8) 
and interleukins 6 (IL-6) (Fig.17) [49].  
 
 
 
 
 
 
 
 
 
Fig.17 Pollard JW.  Nature Reviews Cancer.2004;4:71-78.   
Pro- and anti-tumorigenic properties of macrophages depend on the cytokine 
microenvironment in the tumour. Soluble CSF-1promotes trophic macrophages 
and together with interleukin-6 (IL-6) blocks dendritic cells maturation. In 
contrast cell surface CSF-1 activates cytotoxic macrophages. 
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TAMs produce many factors that help tumour growth, invasion, angiogenesis and 
the deposition/dissolution of connective tissue.  
TAMs express many factors that stimulate tumour proliferation including Epidermal 
Growth Factor (EGF), Platelet Derived Growth Factor (PDGF), Transforming 
Growth Factor (TGF-β), Hepatocytes Growth Factor (HGF) and basic Fibroblast 
Growth Factor (bFGF).  
Angiogenesis is influence by the release of Vascular Endothelial Growth Factor 
(VEGF) and a number of potent proangiogenic cytokines such as TNF-α (Tumour 
Necrosis Factor alpha), IL-8 and IL-1 which, through cyclooxygenase 2 (COX-2), 
upregulate HIF-1, resulting in an increase in the transcription of VEGF. TAMs also 
release NO through the induction of the enzyme inducible NO synthase (iNOS). 
Finally, tumour associated macrophages facilitate tumour invasion through the 
production of enzymes and inhibitors that regulate the digestion of the extracellular 
matrix including matrix metalloproteases (MMPs), plasmin, urokinase-type 
plasminogen activator (uPA) and the uPA receptor (uPAR) [49,52] (Fig.18).  
 
 
 
 
 
 
 
 
1.4.1.1 Depletion of macrophages: clodronate 
Selective in-vivo depletion of macrophages is a widely accepted approach to study 
functions and effects of these cells in biological processes. One of the most 
diffused methods for eliminating macrophages is the liposomes-mediated 
intraphagocytic delivery of drugs belonging to the class of bisphosphonates [53]. 
Fig.18 Mantovani A et al. TRENDS in Immunology.2002;23:549-555.  
Role of tumour associated macrophages (TAMs) in the immunobiology of the 
tumour. 
 32 
Bisphosphonates are structural analogues of inorganic pyrophosphate (PPi), a 
substance that is present in biological liquid, which inhibits the formation and the 
dissolution of calcium phosphate crystals in vitro and the ectopic calcification in 
vivo. It maintains its pharmacological properties only if it is administered through 
the parental way, whereas orally it is degraded by pyrophosphatases enzymes 
present in the endothelial cells of the gastro-intestinal tract.  
Inorganic pyrophosphate has a structure like P-O-P, where two phosphate groups 
are linked to an oxygen atom. By substituting oxygen atom with a carbon atom 
which is linked to two lateral chains, R1 and R2, bisphosphonates are resistant to 
pyrophosphatases action. 
R1 chain binds the mineralized bony matrix, whereas R2 chain inhibits the 
absorptive activity and it differs in the different bisphosphonates (Fig 19) [54]. 
 
 
 
 
 
 
 
 
Many molecules have been synthesized with different lateral chains. Each 
molecule presents different chemical, physical and biological properties. One of the 
most used molecule is the dichloromethylenebisphosphonate (Cl2MBP or 
clodronate) (Tab.2) [55]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.19 www.gibis.org 
Chemical structure of 
bisphosphonates. 
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The mechanism of action of bisphosphonates is not completely understood. 
Anyway, the principal target is the osteoclast. The osteoclast is a multinucleus cell, 
that originates from monocyte line. It is involved in the remodelling of bone matrix 
and in the homeostasis of phosphorus and calcium destroying hydroxyapatite and 
inhibiting the absorption of matrix. 
The bisphosphonates cause morphological and functional alterations in osteoclasts 
including: loss of the brush border, decrease of the production of lactic acid, 
decrease of lysosomal enzymes and prostaglandynes, decrease of 
pyrophosphatases and acid phosphatises which are fundamental for phagocytic 
activity of osteoclast and loss of the function of elimination of intracellular protons. 
The idea is that bisphosphonates bind hydroxyapatite crystals in the areas where 
osteclast erodes the bone by forming holes. During the re-absorptive phase, 
osteoclast acidifies the bone matrix causing the dissolution of hydroxyapatite 
crystals and the free bisphosphonate can be ingested by the ostoclast. 
Consequently, it causes ostecoclast’s apoptosis. Bisphosphonates are clinically 
used for the treatment of osteoporosis, osteitis deformans (Paget's disease of the 
bone), bone metastasis (with or without hyper calcemia), multiple myeloma. 
 
In consideration of the onto-genetically relationship between osteoclasts and 
macrophages, bisphosphonates are proposed as elective drugs for acting on 
macrophages. In addition, an important limit of liposomes, a drug-delivery system, 
has been exploited to target drugs to macrophages. 
Liposomes are one of the most versatile and promising drug-delivery system but 
they are easily phagocytised by macrophages before reaching target organ. 
Tab.2 en.wikipedia.org  
Summary table of different bisphosphonate 
compounds. 
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Liposomes are artificially prepared lipid spheres, consisting of concentric 
phopsholipids bilayers, separated by aqueous compartments. They are prepared 
dispersing phospholipids in an aqueous solution in which drugs, such as  
bisphosphonates molecules, have been dissolved. During the formation of lipid 
bilayers, drug molecules are encapsulated (fig.20) [56].  
 
 
 
 
 
 
 
 
The number of concentric phospholipids bilayers (unilamemmalr or multilamellar), 
the phospholipid composition and the charge of liposomes can be varied: this 
positively or negatively influences the predisposition of macrophages to 
phagocytose liposomes (for example, macrophages internalize with higher 
efficiency negatively charged liposomes) [57].  
The exact mechanism that induces macrophages elimination is not completely 
understood.  
Liposomes are ingested by macrophages and targeted to the phagocytic/endocytic 
pathway; after the fusion with lysosomes, the lipid bilayers of the liposomes are 
disrupted by phospholipases and the bisphosphonate drug released into the cell 
(Fig.21) [53]. 
The high intracellular concentration of drug alters cellular metabolism, possibly by 
modulation of intracellular iron [58] or through a direct effect on the ATP cellular 
metabolism [59]. Macrophages die via both caspases dependent and independent 
mechanisms.  
Fig.20 www.nanolifenutra.com 
Example of liposomes structure. 
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In the thesis’s work we used clodronate encapulated in liposomes, referred as 
Clodro-Lip, as therapy to kill macrophages. About 1% of dissolved clodronate 
appears to be encapsulated in liposomes and the final preparation usually contains 
around 5mg of clodronate/ ml of suspension. 
 
 
 
 
 
 
 
 
 
For experiments with laboratory animals, Clodro-Lip are administered through 
different routes, on the basis of what specific populations of macrophages 
researchers want to study. 
Frequently, and also in our case, Clodro-lip is administered via the intraperitoneal 
route. 
 
1.4.2. [18F]FDG-PET and inflammation 
 
[18F]Fluorine-2-deoxy-D-glucose is the most used radiotracer in oncology. It is used 
to diagnose recurrent lesions and to monitor and follow therapy response. Since 
inflammatory cells are characterized by high glucose uptake, the accumulation of 
[18F]FDG in non-neoplastic cells that infiltrate the neoplasm represents a potential 
confounder, particularly in the peritoneal environment [60,61]. 
Yamada and colleagues studied the distribution of [18F]FDG in a rat model of 
inflammation induced by subcutaneously injection of turpentine oil. The maximum 
Fig.21 van Rooijen N et al. TibTech.1997;15:178-185. 
Mechanism of action of Clodro-Lip.1) Clodro-Lip is ingested by macrofage; 2) 
the vaculum fuses with lysosomes; 3) the lipid bylayers is disrupted and 4) 
clodronate is released in the cell. L= lysosomes; arrowheads= phospholypases. 
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uptake of [18F]FDG was observed one hour after injection of radiopharmaceutical. 
In addition, in the longitudinal study, authors observed an increase of [18F]FDG 
uptake during time until to reach the peak level 4 days after inoculation. The 
highest uptake was found in the external zone of abscess where endothelial cells, 
fibroblasts and macrophages were present [61]. 
However, the performance of [18F]FDG-PET in infections is still not fully elucidated. 
 
Different approaches to investigate the relative role of tumour associated 
inflammatory cells have been proposed. Zhuang et al. investigated a dual time 
imaging method to differentiate malignant to benign lesions both in in vitro studies 
using different tumour cell lines and also in vivo in a rat model inoculated with rat 
malignant mesothelioma cell line. Successively, patients who had dual time 
[18F]FDG-PET scan were retrospectively analyzed. In animal models, the uptake of 
malignant lesions increased over time, instead benign lesion slightly decreased. In 
clinical studies, the SUVs of delayed images from malignant lesions in comparison 
with those of earlier scans increased over time. The SUVs of benign lesions 
decreased during time whereas the SUVs of inflammatory lesions caused by 
radiation therapy remained stable over time. In another work, [18F]FDG uptake after 
chemotherapy was evaluated using human B-lymphoblast cell line Daudi 
inoculated in SCID mice in presence or absence of corticosteroids. Inflammatory 
response in corticosteroids treated group was present but less pronounced and 
earlier [62,63].  
 
In this thesis, we decided to evaluated the uptake of [18F]FDG before or after 
depletion of phagocytes by means of clodronate encapsulated into liposomes, a 
drug able to kill activated macrophages [64,65]. 
 
1.4.3. Structure and function of peritoneum 
 
The peritoneum is a large serous membrane, it extends for 2 m2 occupying a 
surface equivalent to that of skin, lining the abdominal cavity and covers various 
solid organs including liver, spleen, stomach, the first portion of duodenum, small 
intestine, cecum, sigmoid colon and, in females, uterus, fallopian tubes and ovaries. 
In the male it forms a closed sac whereas in the female it communicates with 
exterior through the uterine tubes, the uterus and the vagina. These organs are 
connected each other and with the abdominal wall through connective structures 
(ligaments, folds, mesenteries). Peritoneum is divided in two ligaments: the lesser 
omentum and the greater omentum. The lesser omentum is the double layer of 
peritoneum that extends from the liver to the lesser curvature of the stomach and 
the start of the duodenum. The greater omentum is the double layer that extends 
from the stomach to the posterior abdominal wall after associating with the 
transverse colon (Fig.22) [66].  
It is made up of two serous layer: the parietal layer (outer layer), lining the 
abdominal wall and the visceral layer (inner layer), which tightly envelops the 
abdominal organs. 
The peritoneum is made up of a layer of flattened mesothelial cells of mesenchymal 
origin, resting on a continuous basement membrane supported by submesothelium. 
This layer is kept moist and smooth by a thin film of serous fluid, the peritoneal 
liquid. 
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The submesothelium layer consists of an extracellular matrix made up of different 
types of collagen, glycoproteins, glycosaminoglycans and proteoglycans. The 
subserous space is provided with vascular and lymphatic vessels. 
Embryological, these serous membranes arise from the mesoderm, as membranes 
present in the pleural and pericardial cavities. 
 
 
 
 
 
 
 
The principal function of peritoneum is the protection of abdominal content but it 
performs many other functions as movements, absorption, dialysis, healing power 
and storage of fat. 
 
Protection: it contains phagocytic cells which protect from infections; lymphocytes 
provide both cellular and humoral response; greater omentum has the capability to 
move toward sites of infection and to seal them, preventing spread of infection. 
 
Movement: it permits peristalsis of stomach and intestine and abdominal 
movements during respiration. 
 
Absorption: the mesothelium acts as a semi-permeable membrane across which 
fluids and small molecules can pass. Thus, it can absorb fluid effusions from the 
peritoneal cavity. In addition, water and crystalloids are absorbed directly in the 
blood capillaries whereas colloids pass into lymphatics with the aid of phagocytes. 
The great absorptive power is due  to its large surface area. 
 
Dialysis: metabolites as urea can be removed from the blood by artificial 
circulating fluid through the peritoneal cavity. Therapeutically, considerable amount 
of fluids can be administered through peritoneal cavity. 
 
Fig.22 www.theodora.com/anatomy/the_abdomen.html. 
Horizontal disposition of the peritoneum in the upper part of 
the abdomen. 
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Healing power: the mesothelial cells can transform themselves into fibroblasts, 
which promote healing and wound. They may also form adhesions causing 
obstruction in hollow organs. 
 
Storage of fat: peritoneum has the capability to store large amounts of fat.  
 
1.4.4. Peritoneal liquid 
 
The mesothelium can be considered as a semi-permeable membrane which 
ultrafiltrates plasma, giving rise to a liquid called peritoneal liquid. Moreover, 
mesothelial cells produce a surfactant that facilitates the sliding of abdominal 
viscera. The peritoneal liquid arises principally from plasma transudate, but also 
from macrophages secretion and ovarian exudates, tubal fluid and retrograde 
menstruation in women.  
The peritoneal liquid of normal individuals is characterized by low protein (lower 
than 3g/dl3) and cellular contents. There is always a residual amount of serous fluid 
in the peritoneum of approximately 50-100ml, but this volume widely varies.  
The peritoneal liquid circulates within the peritoneal cavity and it is absorbed in 
particular districts as diaphragm, pelvis and the big epiploon. The motility is 
regulated by gravity, bowels peristalsis and respiratory motion. 
 
1.4.5. Peritoneal carcinosis 
 
The peritoneum is exposed to a variety of threats, including infections, injuries 
(mechanical or induced by surgery procedures) and neoplastic formations. 
 
Peritoneal infections may be: localized, with abscess formation i.e. areas of swollen 
tissue colonized by neutrophils recognized and responding to bacteria; or 
generalized like peritonitis. The peritoneum consistently responds to infectious with 
oedema, inflammation, fibroblastic exudates resulting in adhesions between the 
peritoneal surfaces [67]. 
 
Injury of the peritoneum can be generated by surgical procedure, inflammatory 
responses or ischemic events. In all of these conditions, mesothelial cells are 
damaged and their lining disrupted, leaving an exposed area of submesothelium 
[68]. This situation causes an inflammatory reparative response with leukocyte 
infiltration, cytokine production and enhanced proliferation rate of mesothelial cells. 
Mesothelial hyperplasia is principally a consequence of the increased level of 
growth factors and cytokines produced in the inflamed environment [69].  
Peritoneal carcinosis comprises both primary neoplasms, generated from 
peritoneal tissue and peritoneal disseminations of cancer cells come from tumours 
of abdominal organs. 
The primary peritoneal cancers are subdivided in mesothelioma and lipomatous 
tumours. Mesothelioma arises from tissue of mesothelial origin (pleura, pericardium 
and peritoneum), often in association with asbestos exposure. Peritoneal 
involvement can occur as a single manifestation or coupled to involvement of the 
pleura. Associated conditions are calcification and ascites formation [70]. 
Lipomatous tumours only occasionally involve the peritoneum. They comprise 
benign lipomas, well-differentiated liposarcomas or high-grade liposarcomas and 
myxoid liposarcomas [71].  
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The peritoneal dissemination of cancer cells is the most common malignant 
process that involves peritoneum.  
Tumoral cells, which come from primary neoplasia of intra-abdominal organs, 
reach and pass visceral peritoneum accumulating in the peritoneal liquid. Through 
the peritoneal circulation, tumour cells reach the areas of high absorption rate 
where they can attach and growth with the crescent formation of tumoral masses.  
Progressively, these phenomena involve more districts diffusing carcinosis within 
all abdomen and causing the formation of neoplastic ascites. 
The neoplastic ascite is caused by an anomalous increase of peritoneal liquid, it 
reaches about 8-10 litres, where tumoral cells are present. This increase of 
peritoneal liquid depends on two factors: 
 
- iperproduction of peritoneal liquid by peritoneal cells caused by the 
presence of tumoral cells; 
- production of serum and mucina by tumoral cells. 
 
The formation of carcinosis and ascites lead to an increase of intra-abdominal 
pressure due to a compression of intra-abdominal viscera. 
Different to many malignant tumours, peritoneal carcinosis can remain localized in 
peritoneum without originating in metastases at distant sites for many months or 
years.  
The presence of peritoneal carcinosis represents a prognostic negative factors for 
life expectancy, in addition it also influences the quality of life. 
The main tumours that cause peritoneal carcinosis are: 
 
- ovarian carcinoma; 
- colon carcinoma; 
- stomach carcinoma. 
 
Ovarian carcinoma is the eight most common cancer and the fifth leading cause of 
cancer death among women in the United States. Ovarian carcinoma causes more 
death that any other cancer of the female reproductive system and the rate of 
mortality is about constant since 1982 [72]. Peritoneal carcinosis is present in 
almost 80% of ovarian cancer patients at the diagnosis because of the lack of 
specific initial symptoms and the lack of sensitive screening methods to detect 
early tumoral lesions. 
 
1.4.5.1. Pathological changes in peritoneal liquid 
Pathological conditions induce profound changes in terms of activation and 
adaptation in the peritoneal microenvironment. 
In an experimental model of murine carcinosis, it has been demonstrated that the 
seeding of tumoral cells leads to the production of factors, including VEGF, that 
increase the permeability of peritoneal membrane with resulting fluid accumulation 
[73]. For example, IL-6, M-CSF and DC cells increase in ovarian cancer, 
macrophages in endometriosis and IL-10 in malignant tumours. 
 
1.4.6. Diagnosis and monitoring of peritoneal cancer 
 
Peritoneal carcinosis has been considered a difficult disease to treat with classical 
therapeutics and above all with a chirurgical approach. 
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Peritoneum is not considered such as an organ but like a layer which covers 
abdominal cavity and its organs. 
In recent years, the development of innovative chirurgical techniques has allowed 
to apply a chirurgical approach also to peritoneum cancer. Generally, peritoneal 
carcinosis is treated using systemic chemotherapy in association with chirurgical 
cytoreduction for reducing tumour mass and improving symptoms and the quality of 
life. 
The presence of peritoneal tumours is one the most significant prognostic 
indicators in ovarian cancer  and in colorectal carcinoma. 
Early diagnosis of peritoneal tumours is important to assess cytoreduction. In the 
post-treatment setting, accurate monitoring is essential to plan the best therapy 
and to detect tumour recurrence. 
An early and effective diagnosis is hampered by the lack of sensitive screening 
methods to detect early tumoural lesions. 
Computed Tomography (CT), the actual gold standard for detection of peritoneal 
carcinomatosis, has a low sensitivity. In fact, various factors influences the 
sensitivity of CT, including size, site, morphology of tumour deposit, presence of 
ascites, paucity of intraabdominal fat, adequacy of bowel opacification, and 
concomitant use of peritoneography [74]. In addition peritoneal lavage and biopsy 
often present sample errors. 
MRI permits a good evaluation of parietal and visceral peritoneum covered by fluid, 
but MRI acquisition is long, influenced by artefacts of respiratory movements and 
its spatial resolution is low [75]. 
 
Molecular imaging and Positron Emission Tomography (PET)-based techniques in 
particular represent essential tools for neoplastic patient’s stratification and follow-
up after treatment [76, 77] in many types of common tumours, including lymphoma, 
lung cancer, breast cancer, and colorectal cancer. In table 3, it is presented a 
summary of PET sensitivity and specificity compared to those of CT for several 
malignancies.  
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Tab.3 Margolis D et al. Radiology. 2007;245 :333-
356. 
Summary of PET sensitivity and specificity compared 
to those of CT for several malignancies. 
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[18F]2-fluoro-2-deoxy-D-glucose ([18F]FDG) in association with CT has been 
extensively used for staging and diagnosis of recurrent ovarian cancer [78] and for 
the detection of peritoneal carcinomatosis. Yoshida et al. suggested that [18F]FDG-
PET/CT may improve surgical planning. Moreover, in their work, [18F]FDG-PET has 
been shown to predict response to neoadjuvant chemotherapy and survival in 
advanced ovarian cancer [78]. 
[18F]FDG-PET, in association with CT, is characterized by high sensitivity and high 
positive predict value. Turlakow and colleagues, in their study, evaluated the role of  
[18F]FDG-PET in detecting peritoneal carcinomatosis in patients with stomach, 
ovarian, and adrenal cancer and mesothelioma and to compare the results with CT 
scans in the same patient group. They observed that sensitivity and positive predict 
values increase using both modalities together until reaching 78% and 95% 
respectively [79]. 
 
1.4.7. Preclinical model of peritoneal carcinosis 
 
Development of mouse models is very important to study and understand 
molecular and metabolic changes of a pathological disease and to test and monitor 
new therapeutic strategies. 
A good preclinical disease model should be more similar to the real disease or at 
least it should reproduce the main clinical features of human pathology. In this way, 
information and results obtained in preclinical studies may be translated in clinic 
more easily. 
In vivo studies of preclinical model of peritoneal carcinogenesis have been 
hampered by the inaccessibility of the peritoneal cavity using classic methods.  
The recent availability of dedicated small animal tomographs has enabled the 
longitudinal monitoring of lesions in preclinical settings [80,62]. So far, [18F]FDG-
PET imaging for the monitoring of traditional or innovative therapy has been 
investigated in a limited number of studies particularly in case of peritoneal lesions 
[81-83].  
Most preclinical studies have been conducted on xenograft models that rely on 
human ovarian cancer cells transferred into immuno-deficient mice [84]. 
Unfortunately these models do not fully reproduce the environment of peritoneal 
carcinomatosis, since mice that do not reject human cells lack, by definition, key 
components of the innate or acquired immune system [85, 82]. By the other hand, 
only few murine cell lines of ovarian cancer are available and none of them 
properly reproduced peritoneal lesions characterizing human disease because of 
its very low aggressiveness.  
For these reasons, in our study we established a mouse model based on the 
intraperitoneal injection of murine syngenic TS/A adenocarcinoma cells. This model 
reproduces the main clinical features of human neoplastic peritoneal lesions [86], 
including the presence of an abundant inflammatory infiltrate. 
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2. AIM
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The aim is to set up an in vivo PET method for the in vivo monitoring of preclinical 
model of cancer. In particular we have considered of particular relevance in cancer 
two issues such as tissue hypoxia and inflammation. 
Tumour hypoxia and inflammation connected to peritoneal carcinomatosis are two 
phenomena of strong interest but difficult to study with the traditional analysis 
methods. PET dedicated imaging with its radiopharmaceuticals may be an 
alternative method to study, characterize, detect and monitor these diseases. 
Moreover, the obtained data may be easily transferred to clinic and viceversa, 
clinical information may be used for preclinical model.  
In particular, specific objectives of the study were: 
 
- to characterize and compare two promising hypoxic radiopharmaceuticals 
([18F]FAZA and [64Cu]ATSM) in different cancer models using PET and 
autoradiographic imaging and immunohistochemical analysis. 
 
- to verify the involvement of inflammatory cells in [18F]FDG signal in a   
model of peritoneal carcinosis that is characterized the presence or 
absence of inflammatory component using [18F]FDG-PET. 
 
Hypoxic radiopharmaceuticals were assessed in three types of cancer models 
susceptible to hypoxia: a murine mammary cancer (EMT-6 cell line), a human head 
neck cancer (FaDu cell line) and a human prostate adenocarcinoma (PC-3 cell 
line). Animals were evaluated in vivo using PET and ex-vivo using dual tracers 
autoradiography. Imaging data were successively compared with 
immunohistochemical analysis of specific targets like the generic marker for 
hypoxia (carbonic anhydrase IX or CAIX) and the copper transporters (Ctr-1 and 
ATP7B). 
 
To assess the relative role of inflammatory macrophages and proliferating 
carcinoma cells in [18F]FDG uptake in vivo,  we set up an experimental model of 
peritoneal carcinomatosis and we evaluated the uptake of [18F]FDG before or after 
depletion of phagocytes by means of clodronate encapsulated into liposomes, a 
drug able to kill activated macrophages [64, 65]. We used a murine mammary 
adenocarcinoma cell line (TS/A) because it recapitulates the main features of 
human neoplastic peritoneal lesions [86], including the presence of an abundant 
inflammatory infiltrate. Imaging data were supported by histological and 
immunohistochemical analysis. 
. 
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3. HYPOXIA MODEL
 46 
3.1. Materials and methods  
 
3.1.1. Cellular lines  
 
Murine mammary carcinoma cells (EMT-6), human prostate adenocarcinoma cells 
(PC-3) and human pharyngeal carcinoma cells (FaDu) were purchased by ATCC 
(American Type Colture Collection). Cell lines were routinely cultured at 37°C in a 
5% CO2-humidified incubator. Cell lines were maintained on Complete Medium as 
followed: EMT-6 and PC3 on Waymouth’s Medium (Sigma Aldrich S.r.l.) and D-
MEM medium (Sigma Aldrich) respectively with 10% heat-inactivated fetal calf 
serum (FBS) (Gibco-Invitrogen S.r.l), 100 units/ml penicillin and 100 mg/ml 
streptomycin, 2mM L-glutamine; FaDu on D-MEM Medium (Sigma Aldrich S.r.l.) 
with 10% heat inactivated FBS, 100 units/ml penicillin and 100 mg/ml streptomycin, 
2mM L-glutamine and 1 mM sodium pyruvate. 
 
3.1.2. Animal models 
 
Cells (2 x 106 cells) were injected subcutaneously in the right hind leg. EMT-6 were 
implanted into female BALB/c nu/nu mice and PC-3 and FaDu into male BALB/c 
nu/nu mice. The lesions were weekly monitored using a caliber. Animals were kept 
under specific pathogen-free conditions, handled and maintained according to our 
Institutional Animal Care and Use Committee ethical regulations. All animals were 
purchased by Charles River Laboratories. 
 
3.1.3. Study design 
 
Phase 1: identification in a longitudinal study of the optimal window of tumour 
growth by in vivo PET evaluation of [18F]FDG and [18F]FAZA uptake at different 
times from cells inoculation. PET scan were performed weekly starting from a 
lesions size of  6 x 7 mm. 
Phase 2: comparison of the intratumoural distribution of [18F]FAZA and 
[64Cu]ATSM using in vivo PET in the same animals. 
Phase 3: comparison of the intratumoural distribution of [18F]FAZA and 
[64Cu]ATSM using ex vivo dual isotope autoradiography.   
Phase 4: immunohistochemical evaluation of hypoxia factors as carbonic 
anhydrase IX (CAIX) and Copper transporters as ATP7B (Copper exporter) and 
Ctr1 (Copper importer) in the same tumour sample analyzed using PET. 
 
3.1.4. PET studies 
 
[18F]FDG was synthesized according to European Pharmacopoeia V Edition and it 
was injected with a radiochemical purity greater than 99%. [18F]FAZA and 
[64Cu]ATSM were prepared as previously described [87,88]. For longitudinal 
studies, animals (n= 3 per each line) were injected in the tail vein with 4.19±0.2 
MBq or 3.13±0.42 MBq of [18F]FDG or [18F]FAZA respectively. A hour after 
[18F]FDG injection or 2 hours after [18F]FAZA injection, mice were positioned on the 
PET bed and underwent a 30 minutes dynamic acquisition scan (6 scans of 5 
minutes each) centred on the tumour. During acquisition animals were 
anaesthetized with gas anaesthesia (isoflurane/air 1.5:2).  
In the PET studies of phase 2, mice (n= 5 per each line) were injected 
intravenously with 4.66±0.88 or 3.87±1.03 MBq of [18F]FAZA or [64Cu]ATSM 
respectively. For [18F]FAZA we applied the same procedure previously described, 
for [64Cu]ATSM, animals were acquired at 2 hours and 24 hours after the injection. 
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To compare the intratumoural distribution of the two hypoxic radiotracers, PET 
acquisition were performed on the same mice as followed: at day 1 [18F]FAZA, at 
day 2 early [64Cu]ATSM and at day 3 late [64Cu]ATSM (fig.23). 
 
 
 
 
 
 
3.1.5. PET images analysis 
 
PET data were acquired in list mode using the full axial acceptance angle of the 
scanner (3D mode) and all images were then reconstructed by the expectation 
maximization (EM) algorithm [2]. 
Radioactivity concentration was corrected for physical decay and calibrated in 
order to transform counts per voxel values in MBq/ml. Radiotracers uptake was 
measured using Region of Interest (ROIs) analysis. A circular ROI (area=15mm2) 
was drawn on the tumour region of maximum uptake and another one was drawn 
on a muscle (area=7mm2) as background. Automatically, maximum, mean and 
minimum uptake values and standard deviation were generated. The 
radiopharmaceutical distribution was calculated as tumour to background ratio (T/B 
ratio) of the maximum uptake expressed as percentage of injected dose on tissue 
grams (%ID/g). 
After the analysis, animals were sacrificed and tumours were removed for 
histological analysis. 
Analysis were performed using PMOD 2.7 software (PMOD, Zurich, Switzerland).  
 
3.1.6. Dual-tracer ex-vivo autoradiography 
 
Thanks to the different half life of the two radioisotopes (18F t1/2=110 min; 64Cu 
t1/2=12.7 h), a dual-tracer autoradiography was possible. 
Mice (n= 1 per cell line) were co-injected intravenously with 2.66±0.05 MBq 
[18F]FAZA and 0.4±0.01 MBq [64Cu]ATSM so that we sacrificed mice 3 hours and 2 
hours post-injection of [18F]FAZA and [64Cu]ATSM respectively. After the sacrifice, 
tumours were removed, covered with optimal cutting temperature (OCT) 
compound, frozen at -20°C  and cut using a cryostat  (Cryostat Leica, Wetzlar, 
Germany) into 60 micron thick slices. Slices were fixed in acetone for 4 minutes 
and then the slices were exposed on the imaging plate for 3 hours. Then they were 
scanned with a bioimaging analyzer system (Perkin Elmer, Waltham, 
Massachusetts, USA) to obtain the image of the sum of [18F]FAZA and 
[64Cu]ATSM. After F-18 decay, the slices were re-exposed on the imaging plate 
overnight to obtain the [64Cu]ATSM image. Image analysis were performed using 
Optiquant softwareTM (PerkinElmer, CT, USA): the images of Cu-64 were corrected 
 Days 15 16  
PET 
[18F]FAZA [64CU]ATSM 
early (2h p.i.) 
[64CU]ATSM 
late (24h p.i.)  
Immunohistochemistry 
12 
Fig.23 schematic representation of the study design  
days from implantation 
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pixel per pixel for the isotope decay (t1/2= 762 min) and then subtracted to the 
image of the F-18 and Cu-64 sum scanned the day before. The slices adjacent to 
the cutting slices were used for the immunostaining. 
 
3.1.7. Immunohistochemistry analysis  
 
For the hematoxylin and eosin (H&E) staining, the standard protocol was followed. 
Briefly: hematoxylin (6 min), tap water to wash (20 min), acid alcohol to decolorize 
(1 sec), tap water to wash (5 minutes), Lithium Carbonate (3 sec), tap water to wash 
(5 min) and finally Eosin to counterstain (15 sec). 
For IHC with carbonic anhydrase IX (CAIX), Ctr-1 and ATP7B antibodies, the 
protocol was the follow: tissue samples were deparaffinized for 30’ and rehydrated 
to water in a downgraded series of ethanol. Then, they were flushed in water, heat-
induced antigen retrieval was performed for 30 minutes at 97°C with tris EDTA. 
Then, the endogenous peroxidase activity was blocked for 5 minutes with 3% H2O2. 
After that, the sections were washed in Phosphate-buffered saline with BSA for 5 
minutes and then incubated with the primary antibody as follows: CAIX (1:1500 over 
night, DBA Italia s.r.l., Italy), Ctr-1 (1:1000; ON, DBA Italia s.r.l., Italy), ATP7B 
(1:400; 1h, DBA Italia s.r.l., Italy). After washing, the tissue sections were incubated 
for 30 minutes with antirabbit secondary antibody (1:2) (Kit Rabbit Biocare). 
Successively, the samples were washed in PBS to block non-specific antibody 
binding and incubated for 5’ with DAB (3,3' diaminobenzidine tetrahydrochloride) 
chromogen (Dako). Finally, the tissue sections were counterstained with Mayer’s 
hematoxylin to visualize the signal. 
 
3.2. Results 
 
3.2.1. Comparison of intratumoural uptake of [18F]FDG and [18F]FAZA in 
a longitudinal in vivo PET study  
 
Tumour growth was periodically monitored by caliper and volume calculated as 
follows:  
V = π/6 × D1 × D22  
where D1 is the longer diameter and D2 is the shorter  diameter [89]. 
EMT-6 tumours were significantly larger (p<0.05) than FaDu and PC-3 only at the 
end of the study (Fig.24). 
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Starting to 10 days after cell inoculation, mice weekly underwent to [18F]FDG and 
[18F]FAZA PET acquisitions. In Fig.25 it is possible to observe an increase of a 
central necrotic region where there is not uptake of radiotracers and that was 
maximum at PET3, in particular for EMT-6 and PC-3 tumours. During time, we 
noticed a progressive enlargement of [18F]FAZA uptake areas which only partially 
overlapped with [18F]FDG uptake areas. Moreover [18F]FDG uptake area was 
preferentially concentrated in the outer part of the tumour. 
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Fig.24 Tumour growth graph. At the end of the study EMT-6 tumours were 
significantly larger than FaDu and PC-3. PET1 acquisitions were performed at 9 
and 10 days with [18F]FDG and [18F]FAZA respectively. PET2 acquisitions were 
performed at 16 and 17 days and PET 3 at 21 and 22 days from cell inoculation. 
  
 EMT-6 
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Fig.26 is an example of [18F]FAZA and [18F]FDG imaging fusion performed using 
PMOD software. In FaDu tumour model we observed a partial overlap of [18F]FAZA 
and [18F]FDG uptake areas. Hypoxic areas are localized in the inner part of the 
tumour. 
 
 
PET 1 PET 2 PET 3 
[18F]FDG 
[18F]FAZA 
min max 
PET 1 PET 2 PET 3 
[18F]FDG 
[18F]FAZA 
min max 
Fig.25 Transaxial [18F]FAZA and [18F]FDG PET images of EMT-6 
(top), FaDu (middle) and PC-3 (bottom) tumour model. Yellow 
arrows indicate tumour. The other signal present in the images is 
bladder. Animals were positioned supine 
FaDu 
PC-3 
 51 
 
 
 
 
 
 
Images were then quantified using a ROI analysis. [18F]FDG uptake was not 
significantly different in the three cell lines but it decreased significantly from the first 
to the last PET scan (p<0.05) performed at 3.5 weeks where we observed a wide 
necrotic area. In addition we observed a regional extension of hypoxic areas but we 
failed to observed any increment in absolute values of radiotracer concentration. 
Only in EMT-6 we observed a slightly but significant increase of [18F]FAZA uptake at 
PET2 in comparison to PET1 and PET3 (fig.27). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
[18F]FDG 
[18F]FAZA 
FUSION 
max 
max 
min 
min 
Fig.26 Transaxial [18F]FAZA (middle) and [18F]FDG (top) PET images 
and fusion (bottom) a FaDu tumour model. Animals were positioned 
supine. 
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Histological analysis confirmed the presence of wide necrosis areas at 21 days after 
inoculation (Fig.28). Consequently basing on tumour size, presence of necrotic 
regions and tracers uptake, we choose 2.5 weeks as optimal time window for in vivo 
and ex vivo experiments. 
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Fig.27 Radiopharmaceutical uptake was calculated as tumour to muscle 
ratio (T/M) of percentages of maximum of injected dose per tissue grams. 
[18F]FDG uptake decreased during time in all three lines (A). [18F]FAZA 
uptake was lower than [18F]FDG but constant during time (B). Only in 
EMT-6 [18F]FAZA tumour was significantly higher in PET2 than PET1 and 
3. 
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3.2.2. Comparison of intratumoural uptake of [18F]FAZA and 
[64Cu]ATSM at early and late time in vivo by PET and ex-vivo by dual 
tracers autoradiography 
  
Mice were inoculated with EMT-6, FaDu or PC-3 tumour cancer cells (n=6 for each 
cell line) in the hind right leg. Five mice per each cell line underwent to [18F]FAZA- 
and [64Cu]ATSM-PET as previously described in materials and methods. The 
remaining mice (n=1 per each cell line) were used for a dual tracers 
autoradiography. 
FaDu model confirmed the results obtained by O’Donoghue et al.: there were not 
temporal changes in [64Cu]ATSM uptake which was very similar to that of [18F]FAZA 
[47]. In addition, dual tracers autoradiography performed at early time confirmed 
PET data. The tumours were big and in the central part there was absence of 
uptake because of necrosis (Fig.29). 
 
EMT-6 
FaDu 
PC-3 
5x 
5x 
5x 
20x 
20x 
20x 
Fig.28 Results of histological analysis. The tumours were 
excised at the end of the last PET analysis. In all three tumours, 
it was possible to observe a wide necrosis area. 
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For EMT-6 and PC-3 animals, [64Cu]ATSM images acquired at 24 hrs. were similar 
to those observed after [18F]FAZA administration. In the 2 h images, [64Cu]ATSM 
distribution was more homogenous and diffused whereas in the 24 h images 
[64Cu]ATSM accumulated in the outer areas of the tumour. Using autoradiography 
we confirmed results PET at early time. [64Cu]ATSM tumour uptake was more 
diffused in all tumour areas, in particular in PC-3 model that was smaller and less 
necrotic (fig.30 and 31). 
 
 
 
 
 
 
 
 
 
 
 
 
[18F]FAZA 
[64Cu]ATSM 2h 
[64Cu]ATSM 24h 
T/M = 1.8 
T/M = 3.0 
T/M = 2.3 
PET 
[18F]FAZA 
[64Cu]ATSM 2h 
   
   
Inner Medium External 
Autoradiography 
0.2 µCi/cc 15.0 µCi/cc 
   
H&E Staining 
Fig.29 PET, dual tracer autoradiography and Hematoxil&Eosin staining results 
of FaDu model. For PET images, it is possible to observe transaxial (on the left) 
and sagittal (on the right) view of the tumour. Tumour uptake of both 
radiotracers is similar. In central part there was not uptake because of necrosis. 
Similar uptake of [18F]FAZA and [64Cu]ATSM at early time was also observed 
using autoradiography. At PET, animals were positioned prone. 
 55 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
[18F]FDG 
[18F]FAZA 
[64Cu]ATSM 2h 
[64Cu]ATSM 24h 
T/M = 2.2 
T/M = 2.2 
T/M = 4.7 
T/M = 3.3 
PET 
[18F]FAZA 
[64Cu]ATSM 2h 
 
 
 
 
 
 
Inner Medium External 
Autoradiography 
H&E Staining 
0.2 µCi/cc 15.0 µCi/cc 
 
[18F]FAZA 
[64Cu]ATSM 2h 
[64Cu]ATSM 24h 
0.2 µCi/cc 15.0 µCi/cc 
T/M = 4.1 
T/M = 2.9 
T/M = 2.5 
External 
[18F]FAZA  
Inner 
Autoradiography
   
   
Medium 
[64Cu]ATSM 2h 
H&E PET 
Fig.30 PET, dual tracer autoradiography and Hematoxylin&Eosin staining results 
of EMT-6 model. For PET images, it is possible to observe transaxial (on the left) 
and sagittal (on the right) view of the tumour. During time, it was possible to 
observe changes in [64Cu]ATSM uptake. 24 hours [64Cu]ATSM images is more 
similar to that of [18F]FAZA. In addition, in autoradiography we observed a more 
diffuse [64Cu]ATSM uptake at 2 hours within tumour. At PET, animals were 
positioned prone 
Fig.31 PET, dual tracer autoradiography and Hematoxylin&Eosin staining results 
of PC-3 model. For PET images, it is possible to observe transaxial (on the left) 
and sagittal (on the right) view of the tumour. During time, it was possible to 
observe changes in [64Cu]ATSM uptake. 24 hours [64Cu]ATSM images is more 
similar to that of [18F]FAZA. In addition, in autoradiography we observed a more 
diffuse [64Cu]ATSM uptake at 2 hours within tumour. At PET, animals were 
positioned prone 
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3.2.3. Immunohistochemistry analysis  
 
After sacrifice, tumours were excised and general marker for hypoxia, carbonic 
anhydrase IX (CAIX), Copper transporters (ATP7B and Ctr-1) were evaluated. 
In all three types of tumours, carbonic anhydrase IX stained tumour areas near 
necrosis zones. Ctr1 and ATP7B, stained different tumour areas in these cell lines. 
In EMT-6 the two markers were positive in the same peripheral areas, that 
corresponded also to CAIX positive areas. In FaDu cell lines, Ctr1 staining was 
localized in the same areas of CAIX, while ATP7B displayed a pattern characterized 
by a decreasing gradient from periphery to necrotic areas. In PC-3 tumour, the 
expression of Ctr1 and ATP7B was more homogenous (Fig.32).  
 
 
 
 
 
 
At higher magnification, ATP7B staining was positive for blood vessels in all cell 
lines but cellular localization was different in the three tumours: in EMT-6 and FaDu 
it stained cell cytoplasm whereas in PC-3 we observed a cell membrane 
expression (Fig.33A). Ctr1 staining resulted particularly positive for blood vessels 
only in PC-3 cells while (Fig.33B).  
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Fig.32 Immunohistochemistry of FaDu, EMT-6 and 
PC-3 tumours. 
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3.3. Discussion 
In these studies we tried to compare, in vivo using PET, the distribution of the 
metabolic tracer [18F]FDG and the distribution of the hypoxic tracer [18F]FAZA. In 
addition, to better understand hypoxia ligand distribution mechanism, we compared 
both in vivo and ex vivo the kinetic of regional distribution of specific radiotracers 
[64Cu]ATSM and [18F]FAZA. In the longitudinal study, we noticed a decrease of 
maximum [18F]FDG uptake during time within all tumour whereas a constant 
maximum uptake of [18F]FAZA, associated to a more extended positive area 
respect to that of [18F]FDG. In addition, we observed that [18F]FDG and [18F]FAZA 
displayed a different pattern of distribution within the tumour mass because the first 
ligand preferentially was located in the external part of tumour while the second 
displayed a more uniform distribution, with areas of partial overlapping. In the 
regions of mixed uptake we supposed that the hypoxia condition promoted an 
over-expression of glycolytic markers that increased [18F]FDG uptake. On the 
contrary as explained by Obata et al. and Tanaka et al. [44,45], regions where 
there was only [18F]FDG uptake may be characterized by a high density of 
microvessels which increased O2 supply and cell proliferation. Hematoxylin & eosin 
staining confirmed that the areas, where ligands uptake were not present, were 
necrotic, but for PET we didn’t determine with IHC tumoural markers to confirm our 
hypothesis.  
In the further study of in vivo [18F]FAZA and [64Cu]ATSM comparison we observed 
that this latter displayed a kinetic of distribution similar to that of [18F]FAZA at 24 
hrs after injection for EMT-6 and PC-3 cells but not at 2 hrs. This time-dependent 
kinetics was not present in FaDu lesions, where early and later times images of 
[64Cu]ATSM were similar to that of [18F]FAZA. We observed that generally 
distribution of both tracers was overlapped in the outer region of the tumour mass 
whereas in the inner areas [64Cu]ATSM uptake was higher. Results obtained in 
vivo by PET were confirmed using autoradiography by co-injecting in the same 
mouse the two tracers to detect 2 h post-injection hypoxia with [18F]FAZA and 
[64Cu]ATSM. We didn’t compare [18F]FAZA and [64Cu]ATSM later time distribution. 
Accordingly, for a more complete analysis, experiments will be repeated evaluating 
Cu-64 distribution 24 hours after the injection. A time-dependent distribution was 
previously described by O’Donoghue et al. [47] in rats injected with prostate cancer 
cells R3327-AT but, as observed also in our study, not in animals injected with 
A B 
40x FaDu 40x EMT-6 40x PC-3 40x PC-3 
Blood vessels 
Fig.33 Immunohistochemistry of FaDu, EMT-6 and PC-3 tumours at higher 
magnification. A) In all three tumours ATP7B staining was positive for blood 
vessels. In FaDu and EMT-6, it stained cell cytoplasm, instead in PC-3 
tumour, it stained cell membrane. B) Only in PC-3, Ctr-1 stained blood 
vessels. 
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FaDu cells. The regional [64Cu]ATSM uptake, metabolism and exit are controlled by 
a complex system of transporters and enzymes which can influence its uptake. In 
immunohistochemical analysis, we observed that the generic marker for hypoxia, 
carbonic anhydrase IX (CAIX), stained the tumoural area resulted positive with 
[64Cu]ATSM in all three cell lines. The staining with CAIX was characterized by 
spotted pattern with higher intensity in necrotic surrounding areas. The markers for 
copper transporters, Ctr1 and ATP7B, stained different tumour areas in these cell 
lines. In EMT-6 the two markers were positive in the same peripheral areas, that 
corresponded also to CAIX and [64Cu]ATSM-PET positive areas. In FaDu cell lines, 
Ctr1 staining was localized in the same areas of CAIX (corresponding to 
[64Cu]ATSM-PET positive areas), while ATP7B displayed a pattern characterized 
by a decreasing gradient from periphery to necrotic areas. In PC-3 cells, Ctr1 and 
ATP7B staining were more diffused within tumour as observed with CAIX and 
[64Cu]ATSM-PET. At higher magnification, Ctr1 staining resulted particularly 
positive for blood vessels only in PC-3 cells while ATP7B staining was positive for 
blood vessels in all cell lines. In addition, ATP7B cellular localization was different 
in the three tumours: in EMT-6 and FaDu it stained cell cytoplasm whereas in PC-3 
we observed a cell membrane expression. 
Consequently to these results, the only localization of copper pumps can not 
explain per se the different time-dependent behaviour of [64Cu]ATSM in the three 
cell lines. Other factors like delivery dependence of the high lipophilic [64Cu]ATSM 
may be involved in the cell type kinetics of this tracer and also specific cellular 
characteristics as red-ox potential or intra- and extra-cellular pH may influence 
[64Cu]ATSM uptake. In a recent work, Holland et al. suggested that hypoxia-
selective uptake of [64Cu]ATSM may reside in the stability of the copper (I) anion 
with respect to protonation and ligand dissociation. Moreover, their study supported 
the idea of an involvement of NADH-dependent enzyme in the reduction of the 
copper (II) complexes [111]. Then, despite its high imaging potential, more issue 
will be cleared regarding the mechanism of [64Cu]ATSM binding. In contrast, 
[18F]FAZA behaviour was well established but in comparison to [64Cu]ATSM it 
displayed a lower tumour to noise ratio. Preliminary clinical studies in both non–
small-cell lung 
cancer and cancer of the cervix have suggested that [60Cu]ATSM uptake was 
predictive of response to chemo-radiotherapy [40,41] and the use [64Cu]ATSM 
allows high-quality image [46] 
In conclusion, the use of hypoxic radiopharmaceuticals in association with the use 
of positron emission tomography is a very interesting technique and promising  to 
localize and monitor tumour hypoxia. This method may be used for planning the 
most appropriate therapy and to monitor the response. Nevertheless, they need to 
further studies to understand the different kinetic and behaviour, in particular of 
[64Cu]ATSM, in relationship to the different tumour types. In fact, a limitation of this 
method is represented by the lack of complete information about the real molecular 
characteristic of tumour, like as protein expression during the different stages of 
tumoural growth. An important thing is the characterization and identification of the 
proteomic pattern of normal tumour and hypoxic tumour by correlating it with the 
metabolic changes which can be monitored using PET. In this way it may be 
possible to understand what proteins are present (in particular HIF-1α, PI3K and 
other proteins connected with hypoxia and tumour growth) and in what moment of 
the tumour progression for identifying new possible therapeutic strategies. 
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4. INFLAMMATION MODEL
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4.1. Materials and methods 
 
4.1.1. Mice 
Balb/C female mice (6-7 weeks of age) were purchased from Charles River. 
Animals were kept under specific pathogen-free conditions, handled and 
maintained according to our Institutional Animal Care and Use Committee ethical 
regulations. At the end of experiments, animals were sacrificed by CO2 inhalation. 
 
4.1.2. Cells and tumour analysis 
 
TS/A is murine spontaneous adenocarcinoma originated in Balb/C mice [86]. Cells 
were grown in RPMI (Gibco BRL, Grand Island, NY) containing 10% FBS (South 
American Origin, BioWhittaker-Lonza, B-4800Verviers, Belgium), 2 mM glutamine, 
100 IU/ml penicillin, 100g/ml streptomycin (Gibco BRL, Grand Island, NY). Cells 
were routinely tested for Mycoplasma by MycoAlert Mycoplasma detection kit 
(BioWhittaker-Lonza, B-4800Verviers, Belgium). Tumour lesions were micro-
dissected and either processed for immunohistochemistry (see below) or, when 
indicated, dehydrated in order to associate the net weight to neoplastic load. 
 
4.1.3. Study design 
 
Balb/C mice were intraperitoneally implanted with TS/A adenocarcinoma cells (4 x 
105 cells/mouse). The dose represents the minimum tumour dose that elicited the 
growth of neoplastic lesions in 100% of animals, as determined in preliminary 
experiments. First, we performed a model setting study (n=4) to evaluate the 
feasibility of [18F]FDG-PET to monitor onset and progression of peritoneal 
carcinomatosis, then a longitudinal study (n=12) to evaluate disease progression in 
macrophages competent or depleted mice and finally a single point studies (n=20) 
focusing obtained data. In the model setting study, [18F]FDG-PET was performed at 
4 and 10 days after TS/A adenocarcinoma cells inoculation; the day after the last 
PET acquisition animals were sacrificed for histological analysis. For the 
longitudinal and the single point studies, mice were divided in two groups and 
treated intraperitoneally with dichloromethylenebisphosphonic acid (clodronate; 
1mg clodronate/20mg body weight in 200µl of suspension) in order to deplete 
macrophages or PBS encapsulated into liposomes (“Clodrolip” and “Shamlip”, 
respectively), prepared as described [64] and purchased from 
clodronateliposomes.org. Treatments were administered 6 hours after TS/A 
adenocarcinoma cells injection and consistently (at day 2, 5, 8 and 11 after TS/A 
adenocarcinoma cells inoculation) until the end of study (Fig.34). In the longitudinal 
study mice were evaluated using [18F]FDG-PET at 5, 7, 9, 12 days after cell 
inoculation and sacrificed the day after the last PET acquisition. Additional groups 
of mice (single point study) were evaluated using PET at 7 or 12 days and 
sacrificed at 8 and 13 days after TS/A adenocarcinoma cells inoculation 
respectively (Fig.34). At the moment of necropsy, one mouse per cohort was used 
for immunohistochemical analysis; the rest of the mice were used for the 
assessment of lesion weight (longitudinal and single point studies). 
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4.1.4. PET studies  
[18F]FDG is routinely prepared in our facility for clinical use (European 
Pharmacopeia V ed.) and it was injected with a radiochemical purity greater than 
99%. In vivo imaging studies were performed using a small animal tomograph, the 
YAP-(S)-PET II (I.S.E. s.r.l., Pisa, Italy). After a slight anesthesia with ether animals 
were injected in a tail vein with 4.3 ± 0.3 MBq of [18F]FDG dissolved in 50 µl of 
saline. Immediately before PET acquisition, mice were anesthetized with isoflurane 
(isoflurane/air 1:1) and positioned prone on the tomograph bed with the abdomen 
centered in the tomograph field of view. PET scans started 60 min after tracer 
injection and lasted for 30 min (six frames of five min each). PET data were 
acquired in list mode using the full axial acceptance angle of the scanner (3D 
mode) and then reconstructed with the expectation maximization (EM) algorithm 
[2].  
4.1.5. Image analysis 
To verify the feasibility of [18F]FDG-PET to monitor the growth and diffusion of 
peritoneal carcinomatosis and the effect of macrophages depletion on tracer 
uptake, a visual inspection analysis was applied to PET images. Adjacent 
transaxial [18F]FDG positive slices, depending on the presence of abnormal areas 
of radioactivity accumulation, were selected. Images were also quantified using 
ImageJ [90] and MatLab (MathWorks Inc, Natick; MA) software to obtain the 
following parameters:  
- max [18F]FDG uptake in lesions expressed as percentage of injected dose per 
gram of tissue (max %ID/g); 
- mean [18F]FDG uptake in lesions expressed as percentage of injected dose per 
gram of tissue (mean %ID/g); 
- extension of [18F]FDG uptake areas expressed as tumour volume (cm3). 
To this aim, PET images were calibrated to transform count per voxel values in 
MBq/g and corrected for 18F half-life (108.9 min). Volumes of radioactivity 
accumulation were automatically extracted (mask) using ImageJ software after the 
definition of threshold values according to the procedure described below. In order 
to automatically extract lesion from background radioactivity or non specific uptake 
present in urinary bladder an upper and lower threshold values were selected from 
each mouse PET study. Upper values were identified by centring a circular region 
of interest (ROI, mean area=11 mm2) on the maximum value of radioactivity uptake 
present in the abdominal region. Upper values were selected in order to avoid 
urinary bladder uptake that is higher than that present in lesions. Lower values 
were then defined as the double value of radioactivity concentration measured by 
              
1 day 
Cells 
inoculation PET PET Sacrifice 
0 day 13 days 
PET PET 
 
Treatment 
administration 
 
Single point study 
PET 
Fig.34 Schematic representation of the study design  
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drawing a circular ROI (mean area=7 mm2) on a thorax muscle. The use of thorax 
muscle instead of abdominal background was previously set up and validated in a 
group of normal mice. This procedure was validated also in normal mice in order to 
verify that thresholded maps extracted using this methods did not include 
gastrointestinal activity. Using the thresholds above, lesions masks were 
automatically extracted for each PET study using MatLab software. Mean, 
maximum uptake (± SD) of radioactivity concentration expressed in MBq/g and the 
number of voxels with radioactivity values included in the identified threshold range 
were automatically calculated. Finally radioactivity concentration values were 
transformed into percentage of injected dose per gram of tissue (%ID/g) and 
number of voxel was multiplied by voxel volume (1 voxel=0.00015 cm3). 
Quantification analysis was performed by pooling together animals of longitudinal 
study and single point studies. 
4.1.6. Histological analysis 
After sacrifice, tumour lesions were dissected, fixed in 4% PFA, cryopreserved in 
liquid N2 cooled isopentane and embedded in OCT (Killik, Bio-Optica). Serial 6 µm 
thick sections were treated with 0.3% H2O2 to quench endogenous peroxidase 
activity. To evaluate leukocyte infiltration, tissue sections were incubated in PBS + 
4%BSA (SIGMA) + 0.1% Triton (BDH) and then with biotinilated anti-mouse/LCA 
(Leukocyte Common Antigen) CD45.2 mAb (clone 104, BD Pharmingen); signals 
were revealed with R.T.U horseradish peroxidase streptavidin (Vector 
Laboratories, Burlingame, CA), which was detected using Vector NovaRED 
substrate kit (Vector Laboratories, Burlingame, CA). Slides were counterstained 
with Mayer’s hematoxylin and examined under a Nikon Eclipse 55i microscope 
(Nikon, Tokyo, Japan). Images were captured with Digital Sight DS-5 M digital 
camera (Nikon) using Lucia G software (Laboratory Imaging, Prague, CZ). Parallel 
slides in which the primary mAb had been omitted were identically processed and 
used as negative controls. Stained sections were examined by three independent 
operators blinded to experimental design. 
4.1.7. Viability and apoptosis in vitro assays 
TS/A adenocarcinoma cells were challenged with increasing amounts of liposomes 
containing or not clodronate (5, 10, 20 and 40 µl  of Clodrolip or Shamlip 
suspensions/ml). 16 hours after supernatants were retrieved and frozen and  cells 
were harvested. Apoptotic cells were identified by flow cytometry using the Annexin 
V-FITC Apoptosis Detection Kit (Immunostep Research, Valter Occhiena) 
according to the manufacturer’s instructions. Cytometric analysis was performed 
using a FACS Calibur (Becton Dickinson) and the Cell Quest Software. Data were 
analyzed with FCS Express Software. In parallel, the concentration of lactate 
dehydrogenase (LDH) in the supernatants was verified using the CytoTox-ONETM 
Homogeneous Membrane Integrity Assay (Promega). Analysis was performed by a 
Victor3™ Wallac (1420 Multilabel Counter, Perkin Elmer), according to 
manufacturer’s instructions. As a positive control of necrosis, the supernatant of 
adenocarcinoma cells lysed in the presence of the Triton X100 non ionic detergent 
(1%) was used. 
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4.1.8. Statistical analysis 
Results are expressed as mean ± SD. Experimental differences were tested for 
statistical significance using Student’s t test (unpaired, two sided, p considered 
statistically significant when <0.05), by Graph Pad PRISM Software (version 4.0c for 
Macintosh by Software MacKiev). Correlation was calculated with Pearson test  (two 
tailed, confidence interval 95%9) using Graph Pad PRISM Software (version 4.0c 
for Macintosh by Software MacKiev); linear regression was calculated using Graph 
Pad PRISM Software (version 4.0c for Macintosh by Software MacKiev). 
4.2. Results  
4.2.1. Experimental model of peritoneal carcinomatosis and [18F]FDG 
distribution  
To evaluate the feasibility of [18F]FDG PET to monitor onset and progression of 
peritoneal carcinomatosis, we set up a model of peritoneal carcinomatosis based 
on the intraperitoneal injection of syngenic murine TS/A adenocarcinoma cells in 
Balb/C female mice.  TS/A adenocarcinoma is a spontaneous tumour cell line 
arisen in a Balb/C female retired breeder and expanded in vitro [86]. The model 
nicely recapitulates the histological features of the human disease: 
adenocarcinoma cells distributed along the cavity and yielded several three-
dimensional masses attached to the peritoneal lining. In one week, animals 
developed masses with a microscopic architecture typical of adenocarcinoma 
lesions, with cribriform-like structures (Fig.35A), characterized by scant 
vascularization and huge macrophages infiltration. 
We initially verified whether this model was suitable for [18F]FDG PET study. To 
this aim we performed a model setting pilot study scanning mice at 4 and 10 days 
after TS/A adenocarcinoma cells injection. No evidence of disease was detectable 
at 4 days. At 10 days intense spots of [18F]FDG uptake inside the peritoneum were 
detectable in all animals. These areas corresponded to actual peritoneal neoplastic 
lesions, as verified at necropsy (Fig.35B). 
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4.2.2. Relative contribution of neoplastic cells and tumour associated 
phagocytes to [18F]FDG uptake 
We then studied parallel cohorts of macrophage competent and depleted TS/A 
adenocarcinoma bearing mice. To this aim animals were treated with either 
Shamlip or Clodrolip according to the scheme of Fig.34. The efficiency of peritoneal 
macrophages depletion was assessed analyzing peritoneal cells by flow cytometry, 
and was routinely between 46,5 and 97,9%. Clodrolip had no direct cytotoxic 
effects on adenocarcinoma cells, as verified by the in vitro release of the necrosis 
enzyme LDH (Fig.36), and by the staining with labelled Annexin V, that reveals the 
exposure of anionic phospholipids on the outer plasma membrane, an early event 
in programmed cell death via apoptosis  
We monitored disease progression in macrophages competent or depleted animals 
by [18F]FDG PET at 5, 7, 9, 12 day after TS/A adenocarcinoma cells injection, in a 
longitudinal PET study (Fig.37A-D). Starting at 7 days after TS/A adenocarcinoma 
cells injection, neoplastic lesions of control mice displayed high uptake of [18F]FDG. 
Scattered positive spots of [18F]FDG rapidly increased in terms of intensity and 
extension thereafter, from day 9 to day 12 (Fig.37A). Macrophages were important 
for [18F]FDG accumulation and diffusion: in macrophages-depleted mice we failed 
to detect any relevant uptake at 7 and 9 days. Only at later time (12 days) some 
defined signals could be identified in macrophage-depleted mice (Fig.37C). In both 
cohorts of mice radioactivity corresponded to actual neoplastic lesions, as 
observed by necropsy (Fig.37B and D).  
B 
50 
4 days 10 days 10 days 
a 
b 
A 
min max 
Fig.35 Set up of peritoneal carcinomatosis experimental model. (A) 
Representative picture of haematoxylin and eosin staining of peritoneal TS/A 
adenocarcinoma lesions: neoplastic three-dimensional lesions grew as 
independent masses attached to peritoneal linings or to abdominal organs like 
pancreas (arrowhead). (B) [18F]FDG-PET scans of the abdomen of a 
representative mouse followed in the model setting study. Coronal view (a) of 
the image reconstruction and axial slices (b) taken at the level of tumour 
location (dashed white line). Right panel shows a picture of the same mouse at 
the moment of necropsy. Tumour masses are indicated by yellow arrows. 
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We analyzed by immunohistochemistry the presence and relative proportion of 
inflammatory cells infiltrating peritoneal adenocarcinoma lesions in mice at 7 (early 
effect) and 12 days (late effect) after TS/A adenocarcinoma cells injection (Fig.37E). 
The treatment with Clodrolip drastically reduced the inflammatory infiltrate both at 
early and late time points (Fig.37F). The same result was obtained at 7 days after 
TS/A adenocarcinoma cells injection: radioactivity distribution obtained from PET 
studies corresponded to the location of lesions observed during necropsy. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Mean 
(%) 
SEM 
NT 3,24 1,52 
Shamlip 5 4,36 1,35 
Shamlip 20 7,91 4,40 
Clodrolip 5 10,04 2,16 
Clodrolip 20 6,41 0,01 
A 
B C 
FL
2-
H
 
AnnexinV-FITC 
NT ShamLip ClodroLip 
Fig.36 Clodrolip does not affect TS/A viability in vitro. (A) Representative dot plots of 
AnnexinV+ TS/A incubated for 16 hours in vitro with nominal concentration of 200 
µg/µl of Clodrolip and correspondent volumes of Shamlip or medium (NT) as controls. 
(B) Mean % of apoptotic cells, calculated as % of Annexin V+ TS/A cells, in different 
conditions where nominal concentrations are indicated as 5= 25µg/µl, 20=100µg/µl; 
data are obtained from 2 replicates, 2 independent experiments. (C) LDH release by 
Clodrolip vs Shamlip treated TS/A 16 hours after treatment in different conditions, 
where nominal concentrations are indicated as 5= 25µg/µl, 20=100µg/µl; error bars 
are SD from 2 replicates. 
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Fig.37 Relative contribution of neoplastic cells and macrophages to [18F]FDG uptake. 
[18F]FDG-PET scans of abdomen of representative mice from Shamlip (A) and 
Clodrolip (C) treated cohorts at different time points. Coronal view (a) of the image 
reconstruction and axial slices (b) taken at the level of tumour location (dashed white 
line). (B) and (D) are pictures of scanned mice at the moment of necropsy. Tumour 
masses are indicated by yellow arrows. (E) Immunohistochemical staining for CD45.2 
of neoplastic lesions from representative Shamlip and Clodrolip treated animals, at 
early (8 days) and late (13 days) time points. (F) Quantification of the number of 
CD45.2 positive cells per field of view (FOV - at 20X magnification) infiltrating tumour 
lesions; results are expressed as mean of counts of four fields per tumour mass per 
animal. 
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4.2.3. Quantification and correlations analysis 
To better clarify the effects of macrophages on [18F]FDG distribution we: i) applied 
a quantitative analysis on [18F]FDG-PET images, ii) correlated the results of 
[18F]FDG-PET images quantification with the weight of neoplastic lesions sampled 
post mortem. 
In Fig.38A is possible to observe a representative example of thresholded maps of 
radioactivity distribution and the correspondent PET images of representative mice. 
The tumour volume measured using [18F]FDG-PET  was significantly lower after 
macrophage depletion (0.64±0.40 cm3 vs 0.17±0.19, p<0.005; 0.87±0.29 vs 
0.13±0.13, p<0.0005 and 1.31±0.71 vs 0.53±0.49, p=0.01 at 7, 9 and 12 days after 
TS/A adenocarcinoma cells injection in control and macrophage-depleted mice, 
respectively). At 12 days after TS/A adenocarcinoma cells injection an increase in 
the extension of tumour volume was present in macrophage-depleted animals, thus 
suggesting an escape of tumour growth at the end of the treatment (Fig.38A). 
Mean values of maximum and mean [18F]FDG uptake in thresholded tumour 
regions, expressed as %ID/g, were significantly lower in macrophage-depleted 
mice if compared to control Shamlip treated mice at 9 days (p=0.002 and p=0.02 
respectively) after TS/A adenocarcinoma cells injection (Fig.38B and C). The signal 
at 7 days in depleted animals was independent of the accumulation of phagocytes, 
since the presence of leukocytes was reduced by 92.59% (Fig.37F), indicating that 
the principal contribution to [18F]FDG uptake is given by neoplastic proliferating 
cells. 
The observed increase in [18F]FDG uptake in macrophage-depleted mice from 7 to 
12 days after TS/A adenocarcinoma cells injection was confirmed by the 
quantification of maximum and mean radioactivity concentration (Fig.38B and C, * 
p<0.05). Since we observed that the presence of leukocytes was still reduced at 
the last time point (Fig.37F), the increased in radioactivity possibly reflects a 
renewal of tumour growth. 
Moreover, we directly assessed the tumour load by weighting lesions harvested 
from macrophage-depleted and competent animals. Macrophage depletion was 
associated with a substantial smaller tumour burden 13 days after TS/A 
adenocarcinoma cells inoculation in comparison to the sham group (Fig.39A). This 
observation confirmed the trend observed by [18F]FDG-PET analysis and is in 
agreement with the established trophic action of macrophages. A partial reduction 
in neoplastic load was also observed at an earlier time point (7 days) in 
macrophage-depleted mice (Fig.39C). In addition, the weight of lesions positively 
correlated with the extension of radioactivity uptake measured in vivo using 
[18F]FDG-PET, both at 7 and 12 days after TS/A adenocarcinoma cells injection 
(Fig.39D and B respectively).  
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Fig.38 (A) Axial [18F]FDG-PET scans (a) and re-elaborated images with tumour 
contour masks (b) from two representative mice from Shamlip (upper panel) and 
Clodrolip (bottom panel) treated cohorts analyzed at different time points.  (B) 
Variation of maximum and (C) mean [18F]FDG uptake (expressed as %ID/grams) 
during time in Shamlip and Clodrolip treated cohorts of mice. Error bars represent SD 
of two independent experiments for 7 (n=9 for Shamlip and n=11 for Clodrolip) and 12 
days (n=10 for each group) and one experiment for 9 days (n=5 for Shamlip and n=6 
for Clodrolip). 
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Fig.39 PET information strongly correlates with necropsy. (A) Lesion weight from 
Shamlip and Clodrolip treated cohorts of mice at 12 days after TS/A cell injection. 
Errors bars are SD; n=9 each cohort from 2 independent experiments, * p<0.05. (B) 
Correlation plot between lesion weight (x axis) and volume of tumour measured at 
PET (y axis) of tumours of Shamlip and Clodrolip treated mice at 12 days after TS/A 
cell injection, n=9 from 2 independent experiments. Linear regression curve considers 
both cohorts. Correlation value is r=0.8107. (C) Lesion weight from Shamlip and 
Clodrolip treated cohorts of mice at 7 days after TS/A cell injection. Error bars are SD; 
n=4 for Clodrolip and n=3 for Shamlip. (D) Correlation plot between lesion weight (x 
axis) and volume of tumour measured at PET (y axis) of tumours of Shamlip and 
Clodrolip treated mice at 7 days. Linear regression curve considers both cohorts. 
Correlation value is 0.8368. 
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4.3. Discussion 
Proliferating metabolically active neoplastic cells as well as tumour associated 
inflammatory cells possibly contribute to the uptake of [18F]FDG tracer [91]. 
[18F]FDG uptake by inflammatory cells is responsible for false positive results of 
PET imaging. To overcome the problem of false positives, Zhuang et al. [62] 
applied a kinetic approach based on the different level of glucose metabolism 
targets expressed by cancer and inflammatory lesions. It is well known that 
presence of inflammation may affect the interpretation of PET studies. This effect 
has been observed in PET studies evaluating the effect of radiotherapy as well as 
chemotherapeutic approaches. A transient increase in [18F]FDG uptake has been 
described at early time points after cyclophosphamide administration, an effect that 
can be minimized by corticosteroid co-administration [63]. In order to address this 
issue in the setting of peritoneal carcinomatosis, we established an ad hoc system 
using murine TS/A adenocarcinoma cells intraperitoneally injected in syngeneic 
mice. This model reproduces the main clinical characteristics of the human 
carcinomatosis. We followed tumour spreading and growth in the peritoneal cavity 
by imaging with [18F]FDG-PET. The results demonstrate the feasibility of preclinical 
approaches for the imaging and study of inaccessible sites, like the abdominal 
cavity (Fig.35).  
We validated our imaging results performing a quantification analysis on the 
[18F]FDG-PET images, and found a positive correlation between the extension of 
radioactivity uptake measured by [18F]FDG-PET and the weight of tumour masses 
(Fig.39). Several biochemical changes possibly contribute to the uptake of 
[18F]FDG in neoplastic lesions. Transformed cells are characterized by the aberrant 
expression of membrane glucose transporters [92, 93], like the glucose transporter 
1 -Glut-1, and by the increased activity of glycolytic enzymes, principally 
hexokinase, with an increased glycolytic metabolism even in aerobic conditions 
[16, 94]. The diffusion of drugs and diagnostic tracers in neoplastic tissue is altered 
by the inefficient and leaky blood supply: the tumour associated vascular bed is 
characterized by an highly disorganized structure, enhanced permeability and an 
irregular basement membrane structure [95]. Moreover, the accumulation of 
inflammatory cells is often associated with false positive results in [18F]FDG-PET 
based studies [96, 97] and both the number and activation state of inflammatory 
cells have been demonstrated to contribute to the [18F]FDG uptake [98]. Immune 
activation indeed depends on an increased glucose import, primarily through Glut-
1, which is accompanied by an acceleration of glycolysis [99, 100]. Phagocytes, 
like macrophages and granulocytes, are effective accumulators of [18F]FDG 
because of their constitutively high endocytic activity [101]. 
Here we directly addressed the role of macrophages by comparing neoplastic 
lesions weight and tumour volume measured at [18F]FDG-PET after their in vivo 
pharmacological depletion. Depletion with clodronate encapsulated into liposomes 
is an effective method to achieve the pharmacological elimination of phagocytes in 
preclinical setting in vivo [102]. This “suicide” approach is based on the liposome-
mediated internalization of the small hydrophilic molecule clodronate in 
phagocytes. Clodronate belongs to the pharmacological family of bisphosphonates, 
drugs extensively used in the clinical practice to prevent or inhibit development of 
bone metastases, excessive bone resorption and for inflammatory diseases such 
as rheumatoid arthritis and osteoarthritis. Their mechanism of action, that is not 
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completely understood involves a toxic action on osteoclasts; bisphosphonates 
have been also used for macrophages depletion administered in 
nanoencapsulated form to facilitate cell uptake.  To this aim clodronate is prepared 
encapsulated in artificial lipid spheres (liposomes) [64, 65]. Liposomes are ingested 
by macrophages with high efficiency, targeted to the phagocytic/endocytic pathway 
and digested. The clodronate is accumulated within the phagocytes as soon as the 
liposomes are digested by lysosomal phospholipases. When high intracellular 
clodronate concentration is reached cellular homeostasis is altered and apoptosis 
is eventually induced [64], possibly via modulation of intracellular iron and calcium 
[58] or ATP metabolism [59]. This approach has been used in a large variety of 
experimental settings, as it allows the elimination of resident and infiltrating 
macrophages in various organs depending on the administration route [103].  
The direct role of macrophages in the development of neoplastic lesions in the 
peritoneal cavity has been previously addressed in syngeneic [104-106] and 
xenograft models [107]. In the absence of macrophages we observed a diagnostic 
drop in the maximum radioactivity concentration at lesion site (Fig.38). This is most 
likely due to two combined events: i) macrophages per se uptake and maintain a 
pool of [18F]FDG; ii) macrophages actively support the growth and the metabolic 
activity of the lesions, therefore contributing to the [18F]FDG uptake. The latter 
hypothesis well agrees with the notion that the tumour microenvironment modifies 
the outcome of tumour growth and spreading [48]. TAMs in particular promote 
tissue remodeling and neo-vascularization [108, 109], as they can be educated by 
neoplastic cells to play supportive roles promoting tumour progression and 
metastasis [110]. Macrophages produce and release in the tumoural stroma both 
pro- (like IL-8 and Vascular Endothelial Growth Factor) as well as anti- angiogenic 
factors (like IL-12 and IL-18): the balance among these molecules is the master 
regulator of the vascular progression. In order to shed light on the involvement of 
inflammatory cells in [18F]FDG uptake, we analyzed adenocarcinoma peritoneal 
lesions and we associated the extent of leukocytes infiltration with the extent of the 
signal revealed by [18F]FDG-PET. Clodrolip effectively targeted infiltrating 
phagocytes, thus reducing the total inflammatory infiltrate at day 12 (Fig.37). The 
effect on infiltrate did not however justify the actual drop in the extension of 
radioactivity distribution (Fig.38), suggesting that macrophages per se are not the 
only and principal determinant of observed [18F]FDG distribution and modulation. 
Taken together our results indicate that the tumour volume obtained by imaging 
peritoneal carcinomatosis lesions through [18F]FDG-PET is the result of the 
contribution of both neoplastic and infiltrating inflammatory cells metabolic activity. 
Among them, the principal role is played by the neoplastic cells component since 
we observed that the tumour extension measured with [18F]FDG-PET correlates 
with tumour burden progression and trend. [18F]FDG-PET imaging characteristics 
of neoplastic lesions make this approach particularly attractive in investigating the 
effect of experimental treatment targeting innate and acquired immune cells 
associated with peritoneal cancer and promising for clinical approach to early 
diagnosis of peritoneal carcinogenesis. 
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In conclusion this thesis proposes imaging PET as an interesting and useful 
technique for studying and monitoring changes in metabolic processes as hypoxia 
and glucose metabolism during a neoplasia. 
We investigated the distribution of two hypoxia radiopharmaceutical, [18F]FAZA and 
[64Cu]ATSM, in three tumour cell lines. 
First we set up the best temporal window for studying tumours performing in vivo 
longitudinal [18F]FAZA- and [18F]FDG-PET scan acquisitions. In all three lines we 
observed a partial overlap of the two radiotracers. [18F]FDG was more distributed in 
the peripheral tumour areas near muscle, whereas [18F]FAZA was preferentially 
distributed in the central area of the lesion. 
Successively, we compared [18F]FAZA distribution in EMT-6, FaDu and PC-3 with 
[64Cu]ATSM at early and late time in vivo and ex-vivo. In FaDu, the distribution of 
[64Cu]ATSM was not time-dependent and it was similar to that of [18F]FAZA. In 
EMT-6 and PC-3, [64Cu]ATSM showed a different distribution at 2 and 24 hours. 
The images of the tumours acquired with [64Cu]ATSM at early time were more 
similar to that of [18F]FAZA. These results were also confirmed by double-tracers 
autoradiography.  
We observed that [64Cu]ATSM uptake was influenced by biological and molecular 
characteristics of each cell type. The time-dependent uptake of [64Cu]ATSM can 
not be explained only with the different localization of copper pumps observed in 
immuhistochemical analysis but also by red-ox potential or intra- and extra-cellular 
pH. 
Further proteomic studies will be essential to understand and know what proteins 
are expressed in a precise time of the tumour progression. Proteomic data in 
association with imaging results may be useful to connect molecular changes to 
metabolic processes. 
In this thesis we also define the feasibility of the use of PET technique as a non 
invasive and sensitive method to monitor neoplasms in peritoneal cavity and 
demonstrates that the innate immune response associated to peritoneal carcinosis 
are directly involved in peritoneal tumour establishment.  
We set up a model of peritoneal carcinosis by injected murine mammary 
adenocarcinoma cells in the peritoneum of Balb/c mice. A group of mice were 
macrophage-depleted using clodronate. Using [18F]FDG-PET we monitored 
longitudinally tumour growth and we observed that tumour lesions revealed using 
imaging had the same localization at necropsy. Moreover we found a correlation 
between the volume tumour measured at PET and the tumour weight sampled and 
dried after death.  
Depleted mice showed a slower tumour growth in comparison to control mice, 
confirming that macrophages execute an important role in tumour growth and 
progression above all in the first stage of disease onset. 
This model of peritoneal cancer will be employed to test new therapeutic strategies 
which they will be monitored using [18F]FDG-PET imaging. 
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